var data={"title":"Clinical manifestations and diagnosis of pulmonary sarcoidosis","body":"<div id=\"topicContent\" class=\"utdArticleSection utdStyle\"><div id=\"topicTitle\">Clinical manifestations and diagnosis of pulmonary sarcoidosis</div><dl id=\"topicContributors\"><dt><span> </span>Author:</dt><dd><a href=\"https://www.uptodate.com/contents/clinical-manifestations-and-diagnosis-of-pulmonary-sarcoidosis/contributors\" class=\"contributor contributor_credentials\">Talmadge E King, Jr, MD</a></dd><dt><span> </span>Section Editor:</dt><dd><a href=\"https://www.uptodate.com/contents/clinical-manifestations-and-diagnosis-of-pulmonary-sarcoidosis/contributors\" class=\"contributor contributor_credentials\">Kevin R Flaherty, MD, MS</a></dd><dt><span> </span>Deputy Editor:</dt><dd><a href=\"https://www.uptodate.com/contents/clinical-manifestations-and-diagnosis-of-pulmonary-sarcoidosis/contributors\" class=\"contributor contributor_credentials\">Helen Hollingsworth, MD</a></dd></dl><p class=\"disclosureLink\"><a href=\"https://www.uptodate.com/contents/clinical-manifestations-and-diagnosis-of-pulmonary-sarcoidosis/contributor-disclosure\" class=\"contributor contributor_credentials\">Contributor Disclosures</a></p><div id=\"reviewProcess\"><span>All topics are updated as new evidence becomes available and our <a href=\"https://www.uptodate.com/home/editorial-policy\" target=\"_blank\" class=\"policy policy_editorialpolicy\">peer review process</a> is complete.</span></div><div id=\"literatureReviewDate\"><span class=\"emphasis\">Literature review current through:</span>&#160;Feb 2018.&#160;&#124;&#160;<span class=\"emphasis\">This topic last updated:</span>&#160;Jun 19, 2017.</div><div id=\"topicWhatsNewContainer\"></div><div id=\"topicText\"><p class=\"headingAnchor\" id=\"H1\"><span class=\"h1\">INTRODUCTION</span><span class=\"headingEndMark\">&#160;&#8212;&#160;</span>Sarcoidosis is a multisystem granulomatous disorder of unknown etiology that affects individuals worldwide and is characterized pathologically by the presence of noncaseating granulomas in involved organs. It typically affects young adults, and initially presents with one or more of the following abnormalities:</p><p class=\"bulletIndent1\"><span class=\"glyph\">&#9679;</span>Bilateral hilar adenopathy</p><p class=\"bulletIndent1\"><span class=\"glyph\">&#9679;</span>Pulmonary reticular opacities</p><p class=\"bulletIndent1\"><span class=\"glyph\">&#9679;</span>Skin, joint, <span class=\"nowrap\">and/or</span> eye lesions</p><p/><p>An overview of the clinical manifestations and diagnosis of pulmonary sarcoidosis is presented here. Issues relating to extrapulmonary sarcoidosis and the pathogenesis and treatment of sarcoidosis are discussed separately. (See <a href=\"topic.htm?path=pathology-and-pathogenesis-of-sarcoidosis\" class=\"medical medical_review\">&quot;Pathology and pathogenesis of sarcoidosis&quot;</a> and <a href=\"topic.htm?path=treatment-of-pulmonary-sarcoidosis-initial-therapy-with-glucocorticoids\" class=\"medical medical_review\">&quot;Treatment of pulmonary sarcoidosis: Initial therapy with glucocorticoids&quot;</a> and <a href=\"topic.htm?path=treatment-of-pulmonary-sarcoidosis-disease-refractory-to-glucocorticoid-therapy\" class=\"medical medical_review\">&quot;Treatment of pulmonary sarcoidosis: Disease refractory to glucocorticoid therapy&quot;</a> and <a href=\"topic.htm?path=extrapulmonary-manifestations-of-sarcoidosis\" class=\"medical medical_review\">&quot;Extrapulmonary manifestations of sarcoidosis&quot;</a>.)</p><p class=\"headingAnchor\" id=\"H2\"><span class=\"h1\">EPIDEMIOLOGY</span><span class=\"headingEndMark\">&#160;&#8212;&#160;</span>The prevalence (estimated at 10 to 20 per 100,000 population) and annual incidence of sarcoidosis are not known with certainty. The disease appears to vary in incidence among geographical regions and can also aggregate in families and specific races, being three to four times more common in blacks [<a href=\"https://www.uptodate.com/contents/clinical-manifestations-and-diagnosis-of-pulmonary-sarcoidosis/abstract/1\" class=\"abstract_t\">1</a>]. It has been estimated that the lifetime risk of sarcoidosis in blacks in the United States is 2.4 percent, compared with a lifetime risk of 0.85 percent in whites [<a href=\"https://www.uptodate.com/contents/clinical-manifestations-and-diagnosis-of-pulmonary-sarcoidosis/abstract/2,3\" class=\"abstract_t\">2,3</a>].</p><p>In a single center medical record review in cohort containing Olmsted County, Minnesota residents, 448 incident cases of sarcoidosis were identified from 1976 to 2013, or approximately 10 <span class=\"nowrap\">persons/100,000</span> per year [<a href=\"https://www.uptodate.com/contents/clinical-manifestations-and-diagnosis-of-pulmonary-sarcoidosis/abstract/4\" class=\"abstract_t\">4</a>]. The peak age at incidence for women shifted from 40 to 59 years in 1950 to 50 to 69 years in 2010. For men, the peak age at incidence shifted from 30 to 49 years in 1950 to 40 to 59 years in 2010. Ninety-seven percent had evidence of intrathoracic involvement although only 43 percent had respiratory symptoms. This population was greater than 90 percent white. Data from this cohort confirmed that women tended to be older at the age they developed sarcoidosis [<a href=\"https://www.uptodate.com/contents/clinical-manifestations-and-diagnosis-of-pulmonary-sarcoidosis/abstract/5\" class=\"abstract_t\">5</a>]. In addition, the rate of hospitalization was higher among patients with sarcoidosis than patients without sarcoidosis (rate ratio [RR] of 1.37 [95% confidence interval (CI) 1.24&ndash;1.52]), especially among women with sarcoidosis [<a href=\"https://www.uptodate.com/contents/clinical-manifestations-and-diagnosis-of-pulmonary-sarcoidosis/abstract/6\" class=\"abstract_t\">6</a>].</p><p>In addition, the patient's immunogenetic background may play a role in the clinical manifestations of sarcoidosis, and could underlie the heterogeneity of the illness [<a href=\"https://www.uptodate.com/contents/clinical-manifestations-and-diagnosis-of-pulmonary-sarcoidosis/abstract/7,8\" class=\"abstract_t\">7,8</a>]. Epidemiological studies show significant heterogeneity in disease presentation and severity occurs among different ethnic racial groups [<a href=\"https://www.uptodate.com/contents/clinical-manifestations-and-diagnosis-of-pulmonary-sarcoidosis/abstract/9,10\" class=\"abstract_t\">9,10</a>]. For example, blacks tend to be affected more acutely and with more severe disease than whites, who tend to present with asymptomatic and chronic disease [<a href=\"https://www.uptodate.com/contents/clinical-manifestations-and-diagnosis-of-pulmonary-sarcoidosis/abstract/9\" class=\"abstract_t\">9</a>].</p><p>There are numerous reports of familial clustering of sarcoidosis. The most prominent finding is linkage to a section within MHC on the short arm of chromosome 6. It appears that several alleles confer susceptibility to disease (HLA DR 11, 12, 14, 15, 17) and others seem to be protective (eg, HLA DRI, DR4, and possibly DQ*0202) [<a href=\"https://www.uptodate.com/contents/clinical-manifestations-and-diagnosis-of-pulmonary-sarcoidosis/abstract/7\" class=\"abstract_t\">7</a>].</p><p class=\"headingAnchor\" id=\"H3\"><span class=\"h1\">ETIOLOGY</span><span class=\"headingEndMark\">&#160;&#8212;&#160;</span>Despite an extensive research effort, the exact etiology and pathogenesis of sarcoidosis remain unknown [<a href=\"https://www.uptodate.com/contents/clinical-manifestations-and-diagnosis-of-pulmonary-sarcoidosis/abstract/11-13\" class=\"abstract_t\">11-13</a>]. According to one widely held hypothesis, there are multiple causes of sarcoidosis, and different patterns of illness may in part be related to different underlying causes [<a href=\"https://www.uptodate.com/contents/clinical-manifestations-and-diagnosis-of-pulmonary-sarcoidosis/abstract/9\" class=\"abstract_t\">9</a>]. (See <a href=\"topic.htm?path=pathology-and-pathogenesis-of-sarcoidosis\" class=\"medical medical_review\">&quot;Pathology and pathogenesis of sarcoidosis&quot;</a>.)</p><p class=\"headingAnchor\" id=\"H4\"><span class=\"h1\">CLINICAL MANIFESTATIONS</span></p><p class=\"headingAnchor\" id=\"H5\"><span class=\"h2\">Adolescents and adults</span><span class=\"headingEndMark\">&#160;&#8212;&#160;</span>Sarcoidosis typically presents in patients between 20 and 60 years of age; disease onset is approximately 10 years earlier in blacks than in whites [<a href=\"https://www.uptodate.com/contents/clinical-manifestations-and-diagnosis-of-pulmonary-sarcoidosis/abstract/14\" class=\"abstract_t\">14</a>]. In approximately one-half, the disease is detected incidentally by radiographic abnormalities (eg, bilateral hilar adenopathy, reticular opacities) on a routine chest radiograph prior to the development of symptoms. (See <a href=\"#H8\" class=\"local\">'Chest radiograph'</a> below.) </p><p>Sarcoidosis most frequently involves the lung, but up to 30 percent of patients present with extrathoracic manifestations of sarcoidosis (<a href=\"image.htm?imageKey=PULM%2F76046\" class=\"graphic graphic_table graphicRef76046 \">table 1</a>) [<a href=\"https://www.uptodate.com/contents/clinical-manifestations-and-diagnosis-of-pulmonary-sarcoidosis/abstract/4,15-17\" class=\"abstract_t\">4,15-17</a>]. Diffuse interstitial lung disease is the classic type of lung involvement; other less common pulmonary manifestations include pneumothorax, pleural thickening, chylothorax, and pulmonary hypertension. The extrapulmonary manifestations of sarcoidosis are described separately. (See <a href=\"topic.htm?path=extrapulmonary-manifestations-of-sarcoidosis#H18586365\" class=\"medical medical_review\">&quot;Extrapulmonary manifestations of sarcoidosis&quot;, section on 'Diagnostic approach'</a>.)</p><p>Common presenting respiratory symptoms include cough, dyspnea, and chest pain; these are frequently accompanied by fatigue, malaise, fever, and weight loss [<a href=\"https://www.uptodate.com/contents/clinical-manifestations-and-diagnosis-of-pulmonary-sarcoidosis/abstract/18\" class=\"abstract_t\">18</a>]. Patients over the age of 70 years appear to be more likely to present with systemic symptoms, such as fatigue and anorexia; however, dyspnea and cough are generally present at the same time [<a href=\"https://www.uptodate.com/contents/clinical-manifestations-and-diagnosis-of-pulmonary-sarcoidosis/abstract/19\" class=\"abstract_t\">19</a>]. Systemic inflammation may contribute to muscle weakness and exercise intolerance [<a href=\"https://www.uptodate.com/contents/clinical-manifestations-and-diagnosis-of-pulmonary-sarcoidosis/abstract/20-22\" class=\"abstract_t\">20-22</a>]. Patients should also be asked about new skin lesions (particularly around tattoos or scars), visual changes, dry eyes or mouth, parotid swelling, palpitations, syncope, joint pain or swelling, or muscle weakness. </p><p>Even in the presence of lung parenchymal sarcoidosis, crackles are not commonly heard on chest examination. Wheezing may be present when there is endobronchial involvement or traction bronchiectasis due to scarring. Digital clubbing is rare and typically associated with advanced pulmonary fibrosis. The physical exam findings of extrapulmonary sarcoidosis are discussed separately. (See <a href=\"topic.htm?path=extrapulmonary-manifestations-of-sarcoidosis\" class=\"medical medical_review\">&quot;Extrapulmonary manifestations of sarcoidosis&quot;</a> and <a href=\"topic.htm?path=cutaneous-manifestations-of-sarcoidosis\" class=\"medical medical_review\">&quot;Cutaneous manifestations of sarcoidosis&quot;</a> and <a href=\"topic.htm?path=sarcoid-arthropathy\" class=\"medical medical_review\">&quot;Sarcoid arthropathy&quot;</a> and <a href=\"topic.htm?path=neurologic-sarcoidosis\" class=\"medical medical_review\">&quot;Neurologic sarcoidosis&quot;</a>.)</p><p class=\"headingAnchor\" id=\"H6\"><span class=\"h2\">Children</span><span class=\"headingEndMark\">&#160;&#8212;&#160;</span>Symptomatic sarcoidosis is rare in children. Children of African descent appear to have more severe and extensive disease compared to those of Caucasian or Asian descent. Children between the ages of 8 and 15 develop multisystem disease similar to that described in adults [<a href=\"https://www.uptodate.com/contents/clinical-manifestations-and-diagnosis-of-pulmonary-sarcoidosis/abstract/23\" class=\"abstract_t\">23</a>]. Younger children often present with skin rash, arthritis, and uveitis without apparent lung involvement [<a href=\"https://www.uptodate.com/contents/clinical-manifestations-and-diagnosis-of-pulmonary-sarcoidosis/abstract/24\" class=\"abstract_t\">24</a>]. African American children tend to have higher incidences of lymph node involvement, hyperglobulinemia, and hypercalcemia.</p><p>In a series of Danish children with sarcoidosis, the most common presenting manifestations were erythema nodosum and iridocyclitis [<a href=\"https://www.uptodate.com/contents/clinical-manifestations-and-diagnosis-of-pulmonary-sarcoidosis/abstract/25\" class=\"abstract_t\">25</a>]. Ninety percent of the children had an abnormal chest radiograph.</p><p class=\"headingAnchor\" id=\"H3513219\"><span class=\"h1\">EVALUATION</span><span class=\"headingEndMark\">&#160;&#8212;&#160;</span>A comprehensive initial evaluation should be performed in all patients with suspected sarcoidosis. The purpose of this initial evaluation is to obtain additional data supporting the diagnosis of sarcoidosis while eliminating alternative diagnoses, characterize the severity of pulmonary impairment, and identify extrapulmonary organ involvement that may be amenable to biopsy or require immediate therapy.</p><p>Suggested elements of the evaluation include the following [<a href=\"https://www.uptodate.com/contents/clinical-manifestations-and-diagnosis-of-pulmonary-sarcoidosis/abstract/26\" class=\"abstract_t\">26</a>]:</p><p class=\"bulletIndent1\"><span class=\"glyph\">&#9679;</span>History, including occupational and environmental exposure</p><p class=\"bulletIndent1\"><span class=\"glyph\">&#9679;</span>Full physical examination</p><p class=\"bulletIndent1\"><span class=\"glyph\">&#9679;</span>Laboratory testing</p><p class=\"bulletIndent1\"><span class=\"glyph\">&#9679;</span><a href=\"topic.htm?path=tuberculin-skin-test-drug-information\" class=\"drug drug_general\">Tuberculin skin test</a></p><p class=\"bulletIndent1\"><span class=\"glyph\">&#9679;</span>Posteroanterior chest radiograph and often high resolution computed tomography (HRCT) </p><p class=\"bulletIndent1\"><span class=\"glyph\">&#9679;</span>Pulmonary function tests </p><p class=\"bulletIndent1\"><span class=\"glyph\">&#9679;</span>Electrocardiogram</p><p class=\"bulletIndent1\"><span class=\"glyph\">&#9679;</span>Ophthalmologic examination</p><p/><p class=\"headingAnchor\" id=\"H3513505\"><span class=\"h2\">Laboratory testing</span><span class=\"headingEndMark\">&#160;&#8212;&#160;</span>Laboratory testing usually includes a complete blood count and differential, liver function tests, blood urea nitrogen, creatinine, glucose, electrolytes, serum calcium, and urinalysis [<a href=\"https://www.uptodate.com/contents/clinical-manifestations-and-diagnosis-of-pulmonary-sarcoidosis/abstract/27\" class=\"abstract_t\">27</a>]. We typically obtain serologic testing for HIV infection when evaluating a patient for sarcoidosis. The erythrocyte sedimentation rate and c-reactive protein are nonspecific measures of inflammation and are variably obtained. The serum angiotensin converting enzyme (ACE) level and Kveim tests have limited clinical use, as described below.</p><p>A variety of laboratory abnormalities may be seen in patients with sarcoidosis: </p><p class=\"bulletIndent1\"><span class=\"glyph\">&#9679;</span>Anemia is uncommon. When present, it usually results from the anemia of chronic disease, although hypersplenism, bone marrow involvement, or autoimmune hemolytic anemia can occur in some patients [<a href=\"https://www.uptodate.com/contents/clinical-manifestations-and-diagnosis-of-pulmonary-sarcoidosis/abstract/28-30\" class=\"abstract_t\">28-30</a>].</p><p/><p class=\"bulletIndent1\"><span class=\"glyph\">&#9679;</span>Leukopenia (5 to 10 percent) [<a href=\"https://www.uptodate.com/contents/clinical-manifestations-and-diagnosis-of-pulmonary-sarcoidosis/abstract/30\" class=\"abstract_t\">30</a>], eosinophilia (3 percent) [<a href=\"https://www.uptodate.com/contents/clinical-manifestations-and-diagnosis-of-pulmonary-sarcoidosis/abstract/31\" class=\"abstract_t\">31</a>], and thrombocytopenia (rare) can be seen [<a href=\"https://www.uptodate.com/contents/clinical-manifestations-and-diagnosis-of-pulmonary-sarcoidosis/abstract/32\" class=\"abstract_t\">32</a>].</p><p/><p class=\"bulletIndent1\"><span class=\"glyph\">&#9679;</span>The erythrocyte sedimentation rate is frequently elevated, but is not useful in assessing disease activity.</p><p/><p class=\"bulletIndent1\"><span class=\"glyph\">&#9679;</span>C-reactive protein (CRP) is mildly elevated in about one-third of patients with sarcoidosis, but does not differentiate sarcoidosis from other causes of inflammation and shows only a variable correlation with fatigue among patients with sarcoidosis [<a href=\"https://www.uptodate.com/contents/clinical-manifestations-and-diagnosis-of-pulmonary-sarcoidosis/abstract/33\" class=\"abstract_t\">33</a>]. The relationship between CRP and response to therapy is an area of research [<a href=\"https://www.uptodate.com/contents/clinical-manifestations-and-diagnosis-of-pulmonary-sarcoidosis/abstract/34\" class=\"abstract_t\">34</a>]. </p><p/><p class=\"bulletIndent1\"><span class=\"glyph\">&#9679;</span>Hypercalciuria is more commonly observed than hypercalcemia.</p><p/><p class=\"bulletIndent1\"><span class=\"glyph\">&#9679;</span>A moderate elevation in the serum alkaline phosphatase concentration suggests diffuse granulomatous hepatic involvement. (See <a href=\"topic.htm?path=gastrointestinal-and-hepatic-sarcoidosis#H11\" class=\"medical medical_review\">&quot;Gastrointestinal and hepatic sarcoidosis&quot;, section on 'Hepatic'</a>.)</p><p/><p class=\"bulletIndent1\"><span class=\"glyph\">&#9679;</span>Hypergammaglobulinemia (30 to 80 percent) and a positive rheumatoid factor may be present, but are not usually obtained.</p><p/><p class=\"headingAnchor\" id=\"H3513606\"><span class=\"h3\">Serum markers</span><span class=\"headingEndMark\">&#160;&#8212;&#160;</span>Serologic markers, such as serum angiotensin converting enzyme (ACE), adenosine deaminase, serum amyloid A, and soluble interleukin-2 receptor, have been examined for potential roles in diagnosis or monitoring disease activity, but without clear evidence of utility [<a href=\"https://www.uptodate.com/contents/clinical-manifestations-and-diagnosis-of-pulmonary-sarcoidosis/abstract/35\" class=\"abstract_t\">35</a>]. </p><p>The ACE level is elevated in 75 percent of untreated patients with sarcoidosis [<a href=\"https://www.uptodate.com/contents/clinical-manifestations-and-diagnosis-of-pulmonary-sarcoidosis/abstract/36\" class=\"abstract_t\">36</a>]. However, serum ACE has limited utility as a diagnostic test, due to poor sensitivity (false negative results) and insufficient specificity (almost a 10 percent rate of false positive results) [<a href=\"https://www.uptodate.com/contents/clinical-manifestations-and-diagnosis-of-pulmonary-sarcoidosis/abstract/36-38\" class=\"abstract_t\">36-38</a>]. Other disease processes that have been associated with an elevated serum ACE are listed in the table (<a href=\"image.htm?imageKey=PULM%2F93244\" class=\"graphic graphic_table graphicRef93244 \">table 2</a>). Tissue levels of ACE are typically very high, but are not used clinically. The value of monitoring the ACE level to assess the course of the disease remains unclear. </p><p>Elevated adenosine deaminase (ADA) levels may be found in serum and bronchoalveolar lavage (BAL) fluid in sarcoidosis patients [<a href=\"https://www.uptodate.com/contents/clinical-manifestations-and-diagnosis-of-pulmonary-sarcoidosis/abstract/35\" class=\"abstract_t\">35</a>]. However, given the low sensitivity and specificity, the clinical utilization of ADA is limited. </p><p>Serum amyloid A (SAA) has also been found to be increased in sarcoidosis, but it has also not been shown to be clinically useful [<a href=\"https://www.uptodate.com/contents/clinical-manifestations-and-diagnosis-of-pulmonary-sarcoidosis/abstract/35\" class=\"abstract_t\">35</a>]. </p><p>Serum soluble interleukin-2 receptor (sIL2R) has been suggested as a useful marker for determination of extrapulmonary involvement in sarcoidosis patients [<a href=\"https://www.uptodate.com/contents/clinical-manifestations-and-diagnosis-of-pulmonary-sarcoidosis/abstract/35,39\" class=\"abstract_t\">35,39</a>]. </p><p class=\"headingAnchor\" id=\"H520193235\"><span class=\"h3\">Kveim test</span><span class=\"headingEndMark\">&#160;&#8212;&#160;</span>The Kveim test uses a suspension of heat-sterilized splenic cells from patients with sarcoidosis (the Kveim-Siltzbach reagent) in an intradermal skin test (similar to a <a href=\"topic.htm?path=tuberculin-skin-test-drug-information\" class=\"drug drug_general\">tuberculin skin test</a>) to evoke a sarcoid granulomatous response over approximately three weeks [<a href=\"https://www.uptodate.com/contents/clinical-manifestations-and-diagnosis-of-pulmonary-sarcoidosis/abstract/40\" class=\"abstract_t\">40</a>]. The Kveim test is essentially a research tool due to limited availability of the reagent and concerns about disease transmission with testing.</p><p class=\"headingAnchor\" id=\"H520193263\"><span class=\"h2\">Testing for tuberculosis</span><span class=\"headingEndMark\">&#160;&#8212;&#160;</span>Unless a patient has a well-documented positive <a href=\"topic.htm?path=tuberculin-skin-test-drug-information\" class=\"drug drug_general\">tuberculin skin test</a>, tuberculin skin testing or an interferon gamma release assay is performed to help exclude Mycobacterium tuberculosis infection. Diminished skin test reactivity is expected in sarcoidosis, so a positive test is strong evidence in favor of mycobacterial disease. (See <a href=\"topic.htm?path=use-of-interferon-gamma-release-assays-for-diagnosis-of-latent-tuberculosis-infection-tuberculosis-screening-in-adults\" class=\"medical medical_review\">&quot;Use of interferon-gamma release assays for diagnosis of latent tuberculosis infection (tuberculosis screening) in adults&quot;</a> and <a href=\"topic.htm?path=approach-to-diagnosis-of-latent-tuberculosis-infection-tuberculosis-screening-in-adults\" class=\"medical medical_review\">&quot;Approach to diagnosis of latent tuberculosis infection (tuberculosis screening) in adults&quot;</a>.)</p><p class=\"headingAnchor\" id=\"H7\"><span class=\"h2\">Pulmonary imaging</span><span class=\"headingEndMark\">&#160;&#8212;&#160;</span>Lung involvement occurs in over 90 percent of patients with sarcoidosis [<a href=\"https://www.uptodate.com/contents/clinical-manifestations-and-diagnosis-of-pulmonary-sarcoidosis/abstract/15,37\" class=\"abstract_t\">15,37</a>]. Pulmonary imaging plays an essential role in the diagnosis of sarcoidosis, starting with a chest radiograph, which is often followed by high resolution computed tomography. Other imaging tests, such as fluorine-18-fluorodeoxyglucose-positron emission tomography (FDG-PET), gallium-67, <a href=\"topic.htm?path=thallium-201-drug-information\" class=\"drug drug_general\">thallium-201</a>, and technetium sestamibi (MIBI-Tc) single photon emission computed tomography (SPECT) are used for particular indications, as described below. </p><p class=\"headingAnchor\" id=\"H8\"><span class=\"h3\">Chest radiograph</span><span class=\"headingEndMark\">&#160;&#8212;&#160;</span>All patients being evaluated for possible sarcoidosis should have a chest radiograph. Bilateral hilar adenopathy is a classic finding in sarcoidosis, and the hila may be symmetrically enlarged (in ~50 percent of cases) or the right may be slightly more prominent [<a href=\"https://www.uptodate.com/contents/clinical-manifestations-and-diagnosis-of-pulmonary-sarcoidosis/abstract/32\" class=\"abstract_t\">32</a>]. True unilateral adenopathy is uncommon (&lt;5 percent of cases). The lung parenchymal findings are more varied and include normal, diffuse reticular or ground glass opacities, nodular consolidation, and cystic scarring. Chest radiographic findings have been organized into stages, which give an anatomic guide to lung involvement, but do not reflect disease activity or functional deficits. </p><p>The radiographic stages are as follows:</p><p class=\"bulletIndent1\"><span class=\"glyph\">&#9679;</span><strong>Stage I</strong> &ndash; Stage I is defined by the presence of bilateral hilar adenopathy, which is often accompanied by right paratracheal node enlargement (<a href=\"image.htm?imageKey=PULM%2F58018\" class=\"graphic graphic_diagnosticimage graphicRef58018 \">image 1</a>). Fifty percent of affected patients exhibit bilateral hilar adenopathy as the first expression of sarcoidosis. Regression of hilar nodes within one to three years occurs in 75 percent of such patients, while 10 percent develop chronic enlargement that can persist for 10 years or more. When bilateral hilar adenopathy is associated with erythema nodosum (EN), migratory polyarthralgias, and fever, the diagnosis of Lofgren syndrome is highly likely.</p><p/><p class=\"bulletIndent1\"><span class=\"glyph\">&#9679;</span><strong>Stage II</strong> &ndash; Stage II consists of bilateral hilar adenopathy and reticular opacities (the latter occurring in the upper more than the lower lung zones). These findings are present at initial diagnosis in 25 percent of patients (<a href=\"image.htm?imageKey=PULM%2F78632\" class=\"graphic graphic_diagnosticimage graphicRef78632 \">image 2</a>). Two-thirds of such patients undergo spontaneous resolution, while the remainder either have progressive disease or display little change over time. Patients with stage II disease usually have mild to moderate symptoms, most commonly cough, dyspnea, fever, <span class=\"nowrap\">and/or</span> easy fatigue.</p><p/><p class=\"bulletIndent1\"><span class=\"glyph\">&#9679;</span><strong>Stage III</strong> &ndash; Stage III consists of reticular opacities with shrinking hilar nodes (<a href=\"image.htm?imageKey=PULM%2F51488\" class=\"graphic graphic_diagnosticimage graphicRef51488 \">image 3</a>). Reticular opacities are predominantly distributed in the upper lung zones.</p><p/><p class=\"bulletIndent1\"><span class=\"glyph\">&#9679;</span><strong>Stage IV</strong> &ndash; Stage IV disease is characterized by reticular opacities with evidence of volume loss, predominantly distributed in the upper lung zones (<a href=\"image.htm?imageKey=PULM%2F68742\" class=\"graphic graphic_diagnosticimage graphicRef68742 \">image 4</a>). Conglomerated masses with marked traction bronchiectasis may also be seen. Extensive calcification and cavitation or cyst formation may also be seen [<a href=\"https://www.uptodate.com/contents/clinical-manifestations-and-diagnosis-of-pulmonary-sarcoidosis/abstract/41\" class=\"abstract_t\">41</a>].</p><p/><p>Less commonly, the chest radiograph may show multiple, bilateral lung nodules and minimal hilar adenopathy, findings that may simulate metastatic disease.</p><p>Calcification of hilar or mediastinal lymph nodes becomes more common with longer disease duration; the pattern is nonspecific [<a href=\"https://www.uptodate.com/contents/clinical-manifestations-and-diagnosis-of-pulmonary-sarcoidosis/abstract/32\" class=\"abstract_t\">32</a>]. Pleural involvement is unusual (&lt;5 percent of patients), but can result in lymphocytic exudative effusion, chylothorax, hemothorax, and pneumothorax [<a href=\"https://www.uptodate.com/contents/clinical-manifestations-and-diagnosis-of-pulmonary-sarcoidosis/abstract/42-44\" class=\"abstract_t\">42-44</a>]. (See <a href=\"topic.htm?path=diagnostic-evaluation-of-a-pleural-effusion-in-adults-initial-testing\" class=\"medical medical_review\">&quot;Diagnostic evaluation of a pleural effusion in adults: Initial testing&quot;</a>.)</p><p class=\"headingAnchor\" id=\"H14\"><span class=\"h3\">HRCT scan</span><span class=\"headingEndMark\">&#160;&#8212;&#160;</span>High resolution computed tomography (HRCT) of the chest is typically obtained to evaluate abnormalities seen on a chest radiograph or to evaluate unexplained dyspnea or cough in a patient with a clear chest radiograph. HRCT can detect parenchymal and mediastinal abnormalities that are not seen on the plain chest radiograph (<a href=\"image.htm?imageKey=PULM%2F69424%7EPULM%2F56447%7EPULM%2F79110%7EPULM%2F80035\" class=\"graphic graphic_diagnosticimage graphicRef69424 graphicRef56447 graphicRef79110 graphicRef80035 \">image 5A-D</a>) [<a href=\"https://www.uptodate.com/contents/clinical-manifestations-and-diagnosis-of-pulmonary-sarcoidosis/abstract/41,45-47\" class=\"abstract_t\">41,45-47</a>]:</p><p class=\"bulletIndent1\"><span class=\"glyph\">&#9679;</span>Hilar and mediastinal lymphadenopathy</p><p class=\"bulletIndent1\"><span class=\"glyph\">&#9679;</span>Beaded or irregular thickening of the bronchovascular bundles</p><p class=\"bulletIndent1\"><span class=\"glyph\">&#9679;</span>Nodules along bronchi, vessels, and subpleural regions</p><p class=\"bulletIndent1\"><span class=\"glyph\">&#9679;</span>Bronchial wall thickening</p><p class=\"bulletIndent1\"><span class=\"glyph\">&#9679;</span>Ground glass opacification</p><p class=\"bulletIndent1\"><span class=\"glyph\">&#9679;</span>Parenchymal masses or nodular consolidation, occasionally with cavitation</p><p class=\"bulletIndent1\"><span class=\"glyph\">&#9679;</span>Parenchymal bands</p><p class=\"bulletIndent1\"><span class=\"glyph\">&#9679;</span>Cysts</p><p class=\"bulletIndent1\"><span class=\"glyph\">&#9679;</span>Fibrosis with distortion of the lung architecture and traction bronchiectasis</p><p/><p>HRCT scanning typically reveals a mid-to-upper zone predominance of the lung parenchymal changes. </p><p>The correlation between HRCT findings and histologic abnormalities was examined in a small series that found an association between ground-glass opacities and sarcoid granulomas rather than alveolitis [<a href=\"https://www.uptodate.com/contents/clinical-manifestations-and-diagnosis-of-pulmonary-sarcoidosis/abstract/48\" class=\"abstract_t\">48</a>]. Although lymphocytic alveolitis can occur, it is rarely identified in those with clinically significant sarcoidosis [<a href=\"https://www.uptodate.com/contents/clinical-manifestations-and-diagnosis-of-pulmonary-sarcoidosis/abstract/49\" class=\"abstract_t\">49</a>]. (See <a href=\"topic.htm?path=high-resolution-computed-tomography-of-the-lungs\" class=\"medical medical_review\">&quot;High resolution computed tomography of the lungs&quot;</a>.)</p><p class=\"headingAnchor\" id=\"H15\"><span class=\"h3\">FDG-PET scan</span><span class=\"headingEndMark\">&#160;&#8212;&#160;</span>The role of fluorine-18-fluorodeoxyglucose (18F-FDG) positron emission tomography (PET) in the evaluation of sarcoidosis is unclear. It may be helpful to identify occult lesions that are more accessible to biopsy than lung lesions [<a href=\"https://www.uptodate.com/contents/clinical-manifestations-and-diagnosis-of-pulmonary-sarcoidosis/abstract/28,50\" class=\"abstract_t\">28,50</a>]. This test does not differentiate sarcoidosis from malignancy, as 18F-FDG PET may be positive in both processes. </p><p>The use of other tracers may, in the future, improve the utility of PET imaging in diagnosing sarcoid. In a small study (24 sarcoid, 17 lung cancer), the combination of 18F-FDG and fluorine-18-methyltyrosine (18F-FMT) PET scanning was able to differentiate sarcoidosis from malignancy; sarcoid lesions were positive on 18F-FDG PET, but negative on 18F-FMT PET (both scans are positive in patients with cancer) [<a href=\"https://www.uptodate.com/contents/clinical-manifestations-and-diagnosis-of-pulmonary-sarcoidosis/abstract/51\" class=\"abstract_t\">51</a>]. Additional studies are needed for confirmation. The 18F-FMT tracer may not be available at all institutions. (See <a href=\"topic.htm?path=computed-tomographic-and-positron-emission-tomographic-scanning-of-pulmonary-nodules\" class=\"medical medical_review\">&quot;Computed tomographic and positron emission tomographic scanning of pulmonary nodules&quot;</a>.)</p><p>FDG-PET scanning may also be useful in the evaluation of cardiac sarcoidosis, as a complement to magnetic resonance imaging. (See <a href=\"topic.htm?path=clinical-manifestations-and-diagnosis-of-cardiac-sarcoidosis#H1592590501\" class=\"medical medical_review\">&quot;Clinical manifestations and diagnosis of cardiac sarcoidosis&quot;, section on 'FDG-PET'</a>.)</p><p class=\"headingAnchor\" id=\"H16\"><span class=\"h3\">Other radiotracer scanning</span><span class=\"headingEndMark\">&#160;&#8212;&#160;</span>Gallium-67 is a radioactive tracer that localizes in inflammatory foci, but is taken up minimally, if at all, by normal lungs [<a href=\"https://www.uptodate.com/contents/clinical-manifestations-and-diagnosis-of-pulmonary-sarcoidosis/abstract/52-54\" class=\"abstract_t\">52-54</a>]. It is not recommended in the routine evaluation of sarcoidosis because a negative scan does not exclude disease and increased uptake in the lungs is not specific for sarcoidosis [<a href=\"https://www.uptodate.com/contents/clinical-manifestations-and-diagnosis-of-pulmonary-sarcoidosis/abstract/55\" class=\"abstract_t\">55</a>].</p><p>Gallium scans that show the combination of the &quot;panda&quot; and &quot;lambda&quot; signs are occasionally useful in the diagnosis of sarcoidosis. This testing is used to find support for a diagnosis of sarcoid in the uncommon situation that none of the sites of disease is amenable to biopsy. The so-called &quot;panda&quot; sign occurs when bilateral uptake in the lacrimal and parotid glands is superimposed on the normal uptake by the nasopharyngeal mucosa. The &quot;lambda&quot; sign refers to gallium uptake by the right paratracheal and bilateral hilar lymph nodes results in a pattern similar to the Greek &quot;lambda&quot; symbol. The combination of these signs is felt to be strong evidence in favor of sarcoidosis, although the panda sign alone could be seen in Sj&ouml;gren disease. </p><p>Other types of radiotracer-based scanning may aid in the diagnosis and clinical assessment of patients with sarcoidosis in the future [<a href=\"https://www.uptodate.com/contents/clinical-manifestations-and-diagnosis-of-pulmonary-sarcoidosis/abstract/56,57\" class=\"abstract_t\">56,57</a>]. As an example, <a href=\"topic.htm?path=thallium-201-drug-information\" class=\"drug drug_general\">thallium-201</a> imaging and technetium sestamibi (MIBI-Tc) single photon emission computed tomography (SPECT) are sometimes used in the evaluation of patients with suspected myocardial sarcoid, although magnetic resonance and FDG-PET are generally preferred. (See <a href=\"topic.htm?path=clinical-manifestations-and-diagnosis-of-cardiac-sarcoidosis#H3898522166\" class=\"medical medical_review\">&quot;Clinical manifestations and diagnosis of cardiac sarcoidosis&quot;, section on 'Key diagnostic tests'</a>.)</p><p>Technetium-labeled depreotide binds to somatostatin receptors, which are overexpressed in malignant and inflammatory conditions. A preliminary trial examining Tc-depreotide scanning in sarcoidosis obtained scans in 22 patients with known sarcoidosis [<a href=\"https://www.uptodate.com/contents/clinical-manifestations-and-diagnosis-of-pulmonary-sarcoidosis/abstract/56\" class=\"abstract_t\">56</a>]. Scan results were positive in 18 patients (81 percent), and all four patients with negative total body scans had normal plain chest radiographs, having cleared prior abnormalities since diagnosis. The full operating characteristics of this test are unknown, and its clinical use remains experimental.</p><p class=\"headingAnchor\" id=\"H34\"><span class=\"h2\">Pulmonary function testing</span><span class=\"headingEndMark\">&#160;&#8212;&#160;</span>Pulmonary function tests (PFTs), including spirometry, lung volumes, diffusing capacity for carbon monoxide (DLCO), and six-minute walk test (6MWT), are obtained in patients with pulmonary sarcoidosis to assess the severity of respiratory impairment and to monitor the course of disease with sequential measurements. PFTs are not a reliable means for detecting lung parenchymal sarcoidosis (an HRCT is better), nor do they provide an accurate estimate of the extent of parenchymal disease. In addition, the clinician cannot predict the natural course of lung involvement or the response to therapy solely on the basis of these tests.</p><p>Approximately 20 percent of patients with stage I sarcoid have abnormal PFTs [<a href=\"https://www.uptodate.com/contents/clinical-manifestations-and-diagnosis-of-pulmonary-sarcoidosis/abstract/32\" class=\"abstract_t\">32</a>]. In contrast, PFTs are abnormal in 40 to 70 percent of patients with stage II to IV disease. (See <a href=\"#H8\" class=\"local\">'Chest radiograph'</a> above.)</p><p>PFTs characteristically reveal a restrictive pattern (reduced vital capacity and total lung capacity) associated with a reduction in the DLCO, although it is not unusual for lung function to be normal [<a href=\"https://www.uptodate.com/contents/clinical-manifestations-and-diagnosis-of-pulmonary-sarcoidosis/abstract/58\" class=\"abstract_t\">58</a>]. Endobronchial sarcoidosis may lead to impairment of airflow and obstructive respiratory physiology. </p><p>The 6MWT distance is reduced in the majority of patients with sarcoidosis and correlates with reductions in forced vital capacity and ambulatory pulse oxygen saturation [<a href=\"https://www.uptodate.com/contents/clinical-manifestations-and-diagnosis-of-pulmonary-sarcoidosis/abstract/59\" class=\"abstract_t\">59</a>]. It is thought that the 6MWT provides an integrated assessment of sarcoidosis as it is affected by extrapulmonary factors such as muscle strength, fatigue, and cardiac function [<a href=\"https://www.uptodate.com/contents/clinical-manifestations-and-diagnosis-of-pulmonary-sarcoidosis/abstract/59\" class=\"abstract_t\">59</a>]. (See <a href=\"topic.htm?path=overview-of-pulmonary-function-testing-in-adults\" class=\"medical medical_review\">&quot;Overview of pulmonary function testing in adults&quot;</a>.)</p><p>Arterial blood gases may be normal, or may reveal hypoxemia and hypocapnia (hyperventilation). Exercise may accentuate these abnormalities [<a href=\"https://www.uptodate.com/contents/clinical-manifestations-and-diagnosis-of-pulmonary-sarcoidosis/abstract/60\" class=\"abstract_t\">60</a>]. The main indication for arterial blood gas testing is to assess for hypercapnia, as oxygenation is typically assessed by pulse oxygen saturation at rest and with exertion.</p><p class=\"headingAnchor\" id=\"H272446561\"><span class=\"h1\">DIAGNOSIS</span></p><p class=\"headingAnchor\" id=\"H37\"><span class=\"h2\">Diagnostic approach</span><span class=\"headingEndMark\">&#160;&#8212;&#160;</span>A definitive diagnostic test for sarcoidosis does not exist. Instead, the diagnosis of sarcoidosis requires three elements:</p><p class=\"bulletIndent1\"><span class=\"glyph\">&#9679;</span>Compatible clinical and radiographic manifestations</p><p class=\"bulletIndent1\"><span class=\"glyph\">&#9679;</span>Exclusion of other diseases that may present similarly</p><p class=\"bulletIndent1\"><span class=\"glyph\">&#9679;</span>Histopathologic detection of noncaseating granulomas (<a href=\"image.htm?imageKey=PULM%2F67837%7EPULM%2F67903\" class=\"graphic graphic_picture graphicRef67837 graphicRef67903 \">picture 1A-B</a>)</p><p/><p>These elements are achieved by a comprehensive evaluation in all patients with suspected sarcoidosis, followed by a diagnostic procedure in most cases. In general, involvement of more than one organ system is needed for a diagnosis of sarcoidosis, although biopsy of a second site is not always needed. As an example, the combination of noncaseating granulomas in one organ (eg, skin, lung) and clinical evidence of sarcoid in another (eg, hypercalcemia, bilateral hilar enlargement) would generally be sufficient to make a diagnosis of sarcoidosis.</p><p>The main exceptions to the need for a biopsy are the presence of bilateral hilar adenopathy in an asymptomatic patient (Stage I) who can be monitored without biopsy and the presentation of classical Lofgren's syndrome with fever, erythema nodosum, arthralgias, and bilateral hilar lymphadenopathy. The latter patients typically do not require a biopsy if no alternative explanation for the constellation of findings exists and if the abnormalities resolve quickly and spontaneously. Of note, erythema nodosum lesions should not be biopsied, because the histopathology will demonstrate panniculitis and not granulomas, even if sarcoidosis exists [<a href=\"https://www.uptodate.com/contents/clinical-manifestations-and-diagnosis-of-pulmonary-sarcoidosis/abstract/26\" class=\"abstract_t\">26</a>]. (See <a href=\"topic.htm?path=extrapulmonary-manifestations-of-sarcoidosis#H18586401\" class=\"medical medical_review\">&quot;Extrapulmonary manifestations of sarcoidosis&quot;, section on 'Lofgren syndrome'</a>.)</p><p class=\"headingAnchor\" id=\"H272446495\"><span class=\"h2\">Choice of biopsy site</span><span class=\"headingEndMark\">&#160;&#8212;&#160;</span>Biopsies should be performed on the most accessible lesion that appears to be affected, which may include cutaneous lesions, subcutaneous nodules, palpable lymph nodes, enlarged parotid gland, conjunctival lesions, enlarged lacrimal gland, or certain other ocular lesions. If the patient does not appear to have involvement of one of these sites, the next choice is usually to obtain a biopsy or fine needle aspirate of radiographically enlarged intrathoracic lymph nodes or lung parenchyma.</p><p>Some patients with noncaseating granulomas documented at extrapulmonary sites, still require bronchoscopy, such as those with constitutional symptoms suggestive of infection or atypical clinical or radiographic findings. As an example, patients with cavitary lung disease may require bronchoscopy to exclude mycobacterial and fungal infection prior to initiation of any immunosuppressive therapy. Similarly, patients with an atypical pattern of mediastinal adenopathy often need sampling of their mediastinal nodes. &#160;</p><p>For patients with parenchymal lung disease, but no apparent mediastinal adenopathy or extrapulmonary disease (after a careful search), the decision between a transbronchial lung biopsy versus a thoracoscopic biopsy depends on the degree of suspicion for sarcoidosis. As transbronchial lung biopsy has a high yield in sarcoidosis, it would be an appropriate choice for a patient in whom sarcoidosis is strongly suspected (eg, a young patient with high resolution computed tomography showing beading of the bronchovascular bundles). In contrast, a thoracoscopic biopsy is preferred for patients with a lower likelihood of sarcoidosis and a greater likelihood of an alternative diagnosis that would require a larger specimen for diagnosis. (See <a href=\"topic.htm?path=role-of-lung-biopsy-in-the-diagnosis-of-interstitial-lung-disease\" class=\"medical medical_review\">&quot;Role of lung biopsy in the diagnosis of interstitial lung disease&quot;</a>.)</p><p class=\"headingAnchor\" id=\"H272445606\"><span class=\"h2\">Bronchoscopy</span><span class=\"headingEndMark\">&#160;&#8212;&#160;</span>Flexible bronchoscopy with bronchoalveolar lavage (BAL), endobronchial biopsy, and transbronchial biopsy are traditional methods for the minimally invasive diagnosis of sarcoidosis.</p><p class=\"bulletIndent1\"><span class=\"glyph\">&#9679;</span><strong>Bronchoalveolar lavage</strong> &ndash; BAL can be used as an adjunctive measure to support the diagnosis of sarcoidosis by demonstrating a reduced number of CD8 cells, an elevated CD4 to CD8 ratio, and an increased amount of activated T cells, CD4 cells, immunoglobulins, and IgG-secreting cells [<a href=\"https://www.uptodate.com/contents/clinical-manifestations-and-diagnosis-of-pulmonary-sarcoidosis/abstract/40,61-68\" class=\"abstract_t\">40,61-68</a>]. BAL is also used to exclude infections and malignancy as alternative diagnoses. (See <a href=\"topic.htm?path=basic-principles-and-technique-of-bronchoalveolar-lavage\" class=\"medical medical_review\">&quot;Basic principles and technique of bronchoalveolar lavage&quot;</a> and <a href=\"topic.htm?path=role-of-bronchoalveolar-lavage-in-diagnosis-of-interstitial-lung-disease#H3\" class=\"medical medical_review\">&quot;Role of bronchoalveolar lavage in diagnosis of interstitial lung disease&quot;, section on 'Lymphocytic BAL'</a>.)</p><p/><p class=\"bulletIndent1\">The finding of lymphocytosis in lavage fluid is neither specific nor sensitive for the diagnosis of sarcoidosis. It therefore has the potential for diagnostic misinterpretation. As an example, one study evaluated 128 untreated patients with BAL lymphocytosis due to a variety of causes [<a href=\"https://www.uptodate.com/contents/clinical-manifestations-and-diagnosis-of-pulmonary-sarcoidosis/abstract/63\" class=\"abstract_t\">63</a>]. Although there were limitations to this study, several results were of particular interest: </p><p/><p class=\"bulletIndent2\"><span class=\"glyph\">&#8226;</span>The triad of a CD4 to CD8 ratio greater than four to one, a lymphocyte percentage greater than or equal to 16 percent, and a transbronchial biopsy demonstrating noncaseating granulomas was the most specific test for sarcoidosis. This combination of findings was associated with a 100 percent positive predictive value (PPV) for distinguishing sarcoidosis from other interstitial lung diseases, and an 81 percent PPV for distinguishing sarcoidosis from all other diseases.</p><p/><p class=\"bulletIndent2\"><span class=\"glyph\">&#8226;</span>A CD4 to CD8 ratio less than one had a 100 percent negative predictive value for sarcoidosis. However, this finding should be interpreted with caution in light of case reports of CD8-predominant sarcoidosis.</p><p/><p class=\"bulletIndent2\"><span class=\"glyph\">&#8226;</span>BAL fluid with greater than 2 percent neutrophils or greater than 1 percent eosinophils suggested that sarcoidosis was not the correct diagnosis.</p><p/><p class=\"bulletIndent1\">The identification of D-dimer in BAL fluid also supports the diagnosis of sarcoidosis, although this is largely a research tool. One observational study found that 8 out of 10 patients with sarcoidosis had detectable D-dimer in their BAL fluid (defined as &gt;78 ng D-dimer per mL of concentrated BAL fluid), compared with none of 18 healthy controls [<a href=\"https://www.uptodate.com/contents/clinical-manifestations-and-diagnosis-of-pulmonary-sarcoidosis/abstract/66\" class=\"abstract_t\">66</a>]. Among patients with sarcoidosis, black patients appear more likely than white patients to have D-dimer in their BAL fluid [<a href=\"https://www.uptodate.com/contents/clinical-manifestations-and-diagnosis-of-pulmonary-sarcoidosis/abstract/67\" class=\"abstract_t\">67</a>].</p><p/><p class=\"bulletIndent1\"><span class=\"glyph\">&#9679;</span><strong>Endobronchial and transbronchial lung biopsy</strong> &ndash; Endobronchial and transbronchial biopsies may enable the patient to avoid a surgical biopsy. (See <a href=\"topic.htm?path=role-of-lung-biopsy-in-the-diagnosis-of-interstitial-lung-disease#H4\" class=\"medical medical_review\">&quot;Role of lung biopsy in the diagnosis of interstitial lung disease&quot;, section on 'Transbronchial lung biopsy'</a>.)</p><p/><p class=\"bulletIndent1\">For all patients undergoing flexible bronchoscopy, an airway survey should be performed looking for endobronchial lesions, such as erythema or a nodular, granular, or cobblestone appearance (<a href=\"image.htm?imageKey=PULM%2F111424\" class=\"graphic graphic_picture graphicRef111424 \">picture 2</a>) [<a href=\"https://www.uptodate.com/contents/clinical-manifestations-and-diagnosis-of-pulmonary-sarcoidosis/abstract/69,70\" class=\"abstract_t\">69,70</a>]. Endobronchial disease exists in approximately 40 percent of patients with stage I disease and approximately 70 percent of patients with stages II or III disease [<a href=\"https://www.uptodate.com/contents/clinical-manifestations-and-diagnosis-of-pulmonary-sarcoidosis/abstract/69\" class=\"abstract_t\">69</a>]. Four to six endobronchial biopsies are usually obtained, preferably from a site where the mucosa appears erythematous or from the first and secondary carinas if the mucosa appears normal [<a href=\"https://www.uptodate.com/contents/clinical-manifestations-and-diagnosis-of-pulmonary-sarcoidosis/abstract/71\" class=\"abstract_t\">71</a>]. In sarcoidosis, endobronchial mucosal biopsies are frequently positive and may increase the diagnostic yield, compared to transbronchial biopsies alone [<a href=\"https://www.uptodate.com/contents/clinical-manifestations-and-diagnosis-of-pulmonary-sarcoidosis/abstract/72\" class=\"abstract_t\">72</a>]. In a series of 37 patients with sarcoidosis, endobronchial biopsies had a diagnostic yield of 24 percent and increased the yield over transbronchial biopsy alone by 8 percent.</p><p/><p class=\"bulletIndent1\">Transbronchial lung biopsy has a relatively high yield (50 to 75 percent) among patients suspected of having sarcoidosis on the basis of bilateral hilar adenopathy or compatible lung parenchymal findings on high resolution computed tomography (eg, beaded or irregular thickening along bronchovascular bundles) [<a href=\"https://www.uptodate.com/contents/clinical-manifestations-and-diagnosis-of-pulmonary-sarcoidosis/abstract/73,74\" class=\"abstract_t\">73,74</a>]. The specimens obtained should be used for both culture and histologic stains, including stains for acid-fast bacilli and fungi [<a href=\"https://www.uptodate.com/contents/clinical-manifestations-and-diagnosis-of-pulmonary-sarcoidosis/abstract/75\" class=\"abstract_t\">75</a>]. (See <a href=\"#H14\" class=\"local\">'HRCT scan'</a> above and <a href=\"topic.htm?path=role-of-lung-biopsy-in-the-diagnosis-of-interstitial-lung-disease#H4\" class=\"medical medical_review\">&quot;Role of lung biopsy in the diagnosis of interstitial lung disease&quot;, section on 'Transbronchial lung biopsy'</a>.) </p><p/><p class=\"bulletIndent1\"><span class=\"glyph\">&#9679;</span><strong>Transbronchial needle aspiration</strong> &ndash; Transbronchial needle aspiration (TBNA) can be performed during the same procedure and with the same bronchoscope as transbronchial lung biopsy to obtain cellular or core biopsy tissue from pulmonary nodules and mediastinal nodes. Alternatively, TBNA can be performed with ultrasound guidance (see <a href=\"#H272446331\" class=\"local\">'Endoscopic ultrasound guided needle aspiration'</a> below). As noted above, samples should be sent for pathologic and microbiologic analysis. The technique of TBNA and its role in the diagnosis of sarcoidosis is described separately. (See <a href=\"topic.htm?path=transbronchial-needle-aspiration#H3\" class=\"medical medical_review\">&quot;Transbronchial needle aspiration&quot;, section on 'Technical considerations'</a> and <a href=\"topic.htm?path=transbronchial-needle-aspiration#H15\" class=\"medical medical_review\">&quot;Transbronchial needle aspiration&quot;, section on 'Sarcoidosis'</a>.)</p><p/><p class=\"headingAnchor\" id=\"H272446331\"><span class=\"h2\">Endoscopic ultrasound guided needle aspiration</span><span class=\"headingEndMark\">&#160;&#8212;&#160;</span>Endoscopic ultrasound guided needle aspiration of intrathoracic lymph nodes via esophageal endoscopic ultrasound (EUS) or endobronchial ultrasound (EBUS) has a diagnostic yield of approximately 80 to 90 percent in patients with mediastinal adenopathy and a clinical suspicion of sarcoidosis. The choice between these procedures depends on the available expertise and equipment and the location of enlarged thoracic lymph nodes based on computed tomography (CT). These techniques and their diagnostic yield in sarcoidosis are discussed in greater detail separately. (See <a href=\"topic.htm?path=endoscopic-ultrasound-guided-sampling-of-the-mediastinum-technique-indications-contraindications-and-complications\" class=\"medical medical_review\">&quot;Endoscopic ultrasound-guided sampling of the mediastinum: Technique, indications, contraindications, and complications&quot;</a> and <a href=\"topic.htm?path=endobronchial-ultrasound-technical-aspects\" class=\"medical medical_review\">&quot;Endobronchial ultrasound: Technical aspects&quot;</a> and <a href=\"topic.htm?path=endobronchial-ultrasound-indications-contraindications-and-complications#H2047138272\" class=\"medical medical_review\">&quot;Endobronchial ultrasound: Indications, contraindications, and complications&quot;, section on 'Mediastinal lymphadenopathy of unclear etiology'</a>.)</p><p/><p class=\"headingAnchor\" id=\"H272446222\"><span class=\"h2\">Surgical biopsy of mediastinum and lung</span><span class=\"headingEndMark\">&#160;&#8212;&#160;</span>Mediastinal lymph node biopsy via mediastinoscopy or lung biopsy via thoracoscopy or thoracotomy may be required if less invasive tests are unable to provide a diagnosis. (See <a href=\"topic.htm?path=surgical-evaluation-of-mediastinal-lymphadenopathy\" class=\"medical medical_review\">&quot;Surgical evaluation of mediastinal lymphadenopathy&quot;</a> and <a href=\"topic.htm?path=overview-of-minimally-invasive-thoracic-surgery\" class=\"medical medical_review\">&quot;Overview of minimally invasive thoracic surgery&quot;</a>.)</p><p>Lymph node biopsy via mediastinoscopy is positive in 60 percent of patients with bilateral hilar adenopathy and a clear chest radiograph [<a href=\"https://www.uptodate.com/contents/clinical-manifestations-and-diagnosis-of-pulmonary-sarcoidosis/abstract/32\" class=\"abstract_t\">32</a>]. Sometimes, a mediastinal lymph node biopsy is examined by frozen section while the patient remains under anesthesia. If the lymph node does not reveal granulomas, a lung biopsy is obtained by thoracoscopy or thoracotomy, but the patient is spared the lung biopsy if the lymph node reveals noncaseating granulomas. However, if the lung parenchymal findings are atypical for sarcoidosis, both procedures may be necessary. All biopsy specimens should undergo histopathologic analysis, special staining for mycobacteria and fungi, and culture for mycobacteria and fungi. (See <a href=\"topic.htm?path=role-of-lung-biopsy-in-the-diagnosis-of-interstitial-lung-disease\" class=\"medical medical_review\">&quot;Role of lung biopsy in the diagnosis of interstitial lung disease&quot;</a>.)</p><p class=\"headingAnchor\" id=\"H272446686\"><span class=\"h2\">Histopathology</span><span class=\"headingEndMark\">&#160;&#8212;&#160;</span>The characteristic morphologic feature of sarcoidosis is the noncaseating granuloma. In the lung, granulomas are most commonly found in the alveolar septa, the walls of bronchi, and along the pulmonary arteries and veins. Sarcoid granuloma formation is probably preceded by an alveolitis that involves the interstitium more than the alveolar spaces and is characterized by the accumulation of inflammatory cells, including monocytes, macrophages, and lymphocytes [<a href=\"https://www.uptodate.com/contents/clinical-manifestations-and-diagnosis-of-pulmonary-sarcoidosis/abstract/76,77\" class=\"abstract_t\">76,77</a>]. (See <a href=\"topic.htm?path=pathology-and-pathogenesis-of-sarcoidosis\" class=\"medical medical_review\">&quot;Pathology and pathogenesis of sarcoidosis&quot;</a>.)</p><p>The sarcoid granuloma is a focal, chronic inflammatory reaction formed by the accumulation of epithelial cells, monocytes, lymphocytes, macrophages, and fibroblasts [<a href=\"https://www.uptodate.com/contents/clinical-manifestations-and-diagnosis-of-pulmonary-sarcoidosis/abstract/78\" class=\"abstract_t\">78</a>]. Multinucleated giant cells are frequently found among the epithelioid cells within the granuloma follicle and often have cytoplasmic inclusions, such as asteroid bodies, Schaumann bodies, and birefringent crystalline particles (calcium oxalate and other calcium salts) (<a href=\"image.htm?imageKey=PULM%2F83308\" class=\"graphic graphic_picture graphicRef83308 \">picture 3</a> and <a href=\"image.htm?imageKey=PULM%2F83306\" class=\"graphic graphic_picture graphicRef83306 \">picture 4</a> and <a href=\"image.htm?imageKey=PULM%2F83307\" class=\"graphic graphic_picture graphicRef83307 \">picture 5</a>) [<a href=\"https://www.uptodate.com/contents/clinical-manifestations-and-diagnosis-of-pulmonary-sarcoidosis/abstract/79\" class=\"abstract_t\">79</a>]. Most sarcoid granulomas gradually resolve and leave few or no residual manifestations of previous inflammation. Small amounts of central fibrinoid necrosis may be seen, but large amounts of necrosis suggest an alternate diagnosis or necrotizing sarcoid granulomatosis [<a href=\"https://www.uptodate.com/contents/clinical-manifestations-and-diagnosis-of-pulmonary-sarcoidosis/abstract/80,81\" class=\"abstract_t\">80,81</a>]. (See <a href=\"topic.htm?path=interpretation-of-lung-biopsy-results-in-interstitial-lung-disease#H5487037\" class=\"medical medical_review\">&quot;Interpretation of lung biopsy results in interstitial lung disease&quot;, section on 'Sarcoidosis'</a>.)</p><p>Sarcoid-like histopathologic changes can be seen in lymph nodes from patients with neoplastic diseases such as Hodgkin disease and other lymphoproliferative disorders, germ cell testicular tumors, breast cancer, renal cell carcinoma, leiomyosarcoma, and ovarian mucinous cystadenoma, among others [<a href=\"https://www.uptodate.com/contents/clinical-manifestations-and-diagnosis-of-pulmonary-sarcoidosis/abstract/82-86\" class=\"abstract_t\">82-86</a>]. Thus, caution is advised when patients present with sarcoid-like granulomas in a lymph node, but without other typical features of sarcoidosis.</p><p class=\"headingAnchor\" id=\"H3513152\"><span class=\"h1\">DIFFERENTIAL DIAGNOSIS</span><span class=\"headingEndMark\">&#160;&#8212;&#160;</span>An essential part of the diagnosis of sarcoidosis is the exclusion of alternative possibilities, and several settings are particularly prone to diagnostic difficulty. As an example, diagnosis may be difficult in the absence of extrapulmonary manifestations, bilateral hilar lymphadenopathy, or mediastinal lymphadenopathy. Similarly, the presence of HIV infection, a history of exposure to potential occupational or environmental agents, <span class=\"nowrap\">and/or</span> prominent systemic symptoms may make the diagnosis more challenging [<a href=\"https://www.uptodate.com/contents/clinical-manifestations-and-diagnosis-of-pulmonary-sarcoidosis/abstract/87,88\" class=\"abstract_t\">87,88</a>]. Prominent systemic symptoms (eg, fever, night sweats, weight loss, <span class=\"nowrap\">and/or</span> fatigue) increase the concern for infection or malignancy. For the latter patients, a lymph node biopsy showing noncaseating granulomas needs to be carefully examined to exclude concomitant malignancy [<a href=\"https://www.uptodate.com/contents/clinical-manifestations-and-diagnosis-of-pulmonary-sarcoidosis/abstract/89-91\" class=\"abstract_t\">89-91</a>]. (See <a href=\"#H272446686\" class=\"local\">'Histopathology'</a> above.)</p><p>The list of granulomatous lung diseases other than sarcoidosis includes the following (see <a href=\"topic.htm?path=interpretation-of-lung-biopsy-results-in-interstitial-lung-disease#H11388828\" class=\"medical medical_review\">&quot;Interpretation of lung biopsy results in interstitial lung disease&quot;, section on 'Granulomatous lung diseases'</a>):</p><p class=\"bulletIndent1\"><span class=\"glyph\">&#9679;</span>Mycobacterial infection &ndash; Tuberculosis and atypical mycobacterial infections are in the differential of sarcoidosis and granulomatous lung disease. Thus, all biopsy specimens should be examined with special stains for mycobacteria, and cultures obtained whenever possible. (See <a href=\"topic.htm?path=clinical-manifestations-and-complications-of-pulmonary-tuberculosis\" class=\"medical medical_review\">&quot;Clinical manifestations and complications of pulmonary tuberculosis&quot;</a> and <a href=\"topic.htm?path=overview-of-nontuberculous-mycobacterial-infections-in-hiv-negative-patients\" class=\"medical medical_review\">&quot;Overview of nontuberculous mycobacterial infections in HIV-negative patients&quot;</a>.)</p><p/><p class=\"bulletIndent1\"><span class=\"glyph\">&#9679;</span>Fungal infections &ndash; Fungal infections (eg, histoplasmosis, blastomycosis, <em>Pneumocystis jirovecii</em>) are in the differential of sarcoidosis. Thus, all biopsy specimens should be examined with special stains for fungus and cultures of bronchoalveolar lavage fluid obtained whenever possible. In areas endemic for histoplasmosis, antigen testing of urine, serum, and bronchoalveolar lavage fluid should also be performed. (See <a href=\"topic.htm?path=diagnosis-and-treatment-of-pulmonary-histoplasmosis\" class=\"medical medical_review\">&quot;Diagnosis and treatment of pulmonary histoplasmosis&quot;</a> and <a href=\"topic.htm?path=clinical-manifestations-and-diagnosis-of-blastomycosis#H4\" class=\"medical medical_review\">&quot;Clinical manifestations and diagnosis of blastomycosis&quot;, section on 'Pulmonary involvement'</a> and <a href=\"topic.htm?path=clinical-presentation-and-diagnosis-of-pneumocystis-pulmonary-infection-in-hiv-infected-patients\" class=\"medical medical_review\">&quot;Clinical presentation and diagnosis of Pneumocystis pulmonary infection in HIV-infected patients&quot;</a>.)</p><p/><p class=\"bulletIndent1\"><span class=\"glyph\">&#9679;</span>Hypersensitivity pneumonitis &ndash; Hypersensitivity pneumonitis (HP, also called extrinsic allergic alveolitis) can be misdiagnosed as sarcoidosis if the history of exposures to potential antigens is missed. A detailed history of occupational exposures will help to exclude many causes of hypersensitivity pneumonitis. HP granulomas are generally located near respiratory or terminal bronchioles, while sarcoid granulomas have a lymphatic pattern around bronchovascular structures. Compared with sarcoid granulomas, HP granulomas are smaller, less discrete, and associated with greater interstitial chronic inflammation. (See <a href=\"#H272446686\" class=\"local\">'Histopathology'</a> above and <a href=\"topic.htm?path=diagnosis-of-hypersensitivity-pneumonitis-extrinsic-allergic-alveolitis#H13\" class=\"medical medical_review\">&quot;Diagnosis of hypersensitivity pneumonitis (extrinsic allergic alveolitis)&quot;, section on 'Lung biopsy'</a>.)</p><p/><p class=\"bulletIndent1\"><span class=\"glyph\">&#9679;</span>Pneumoconiosis &ndash; Certain pneumoconioses, especially chronic beryllium disease, can mimic sarcoidosis radiographically and pathologically. The diagnosis of chronic beryllium disease is based on a careful occupational history and, when needed, a blood beryllium lymphocyte proliferation test. (See <a href=\"topic.htm?path=chronic-beryllium-disease-berylliosis\" class=\"medical medical_review\">&quot;Chronic beryllium disease (berylliosis)&quot;</a>.)</p><p/><p class=\"bulletIndent1\"><span class=\"glyph\">&#9679;</span>Drug-induced hypersensitivity &ndash; Drug-induced hypersensitivity with granuloma formation has been described with a number of agents, including <a href=\"topic.htm?path=methotrexate-drug-information\" class=\"drug drug_general\">methotrexate</a>, <a href=\"topic.htm?path=etanercept-including-biosimilars-of-etanercept-drug-information\" class=\"drug drug_general\">etanercept</a>, <a href=\"topic.htm?path=infliximab-including-biosimilars-of-infliximab-drug-information\" class=\"drug drug_general\">infliximab</a>, <a href=\"topic.htm?path=adalimumab-including-biosimilars-of-adalimumab-drug-information\" class=\"drug drug_general\">adalimumab</a>, azacytidine, <a href=\"topic.htm?path=oxaliplatin-drug-information\" class=\"drug drug_general\">oxaliplatin</a>, <a href=\"topic.htm?path=amoxicillin-drug-information\" class=\"drug drug_general\">amoxicillin</a>, <a href=\"topic.htm?path=sirolimus-drug-information\" class=\"drug drug_general\">sirolimus</a>, <a href=\"topic.htm?path=fluoxetine-drug-information\" class=\"drug drug_general\">fluoxetine</a>, and intravesicular Bacillus Calmette-Guerin (BCG) [<a href=\"https://www.uptodate.com/contents/clinical-manifestations-and-diagnosis-of-pulmonary-sarcoidosis/abstract/92-97\" class=\"abstract_t\">92-97</a>]. </p><p/><p class=\"bulletIndent1\"><span class=\"glyph\">&#9679;</span>Pulmonary histiocytic disorders &ndash; Pulmonary Langerhans cell histiocytosis (eosinophilic granuloma) and Erdheim-Chester disease, another histiocytic proliferation, are causes of upper lung zone inflammation and scarring. They are differentiated on the basis of biopsy results. Langerhans cells are S-100 and CD1a positive on staining. Erdheim-Chester disease cells express the histiocyte marker CD68, but unlike Langerhans cell histiocytosis, do not express CD1a or S100. (See <a href=\"topic.htm?path=pulmonary-langerhans-cell-histiocytosis\" class=\"medical medical_review\">&quot;Pulmonary Langerhans cell histiocytosis&quot;</a> and <a href=\"topic.htm?path=erdheim-chester-disease\" class=\"medical medical_review\">&quot;Erdheim-Chester disease&quot;</a>.) </p><p/><p class=\"bulletIndent1\"><span class=\"glyph\">&#9679;</span>Foreign body granulomatosis &ndash; Foreign body granulomatosis (FBG) can be caused by aspiration or intravenous injection of foreign materials. The histopathology of FBG typically consists of perivascular fibrosis and aggregates of multinucleated giant cells and granulomas. Polarizable material may be seen within the granulomas and giant cells, or extracellularly in the vessel wall. (See <a href=\"topic.htm?path=foreign-body-granulomatosis\" class=\"medical medical_review\">&quot;Foreign body granulomatosis&quot;</a>.)</p><p/><p class=\"bulletIndent1\"><span class=\"glyph\">&#9679;</span>Diseases associated with vascular inflammation &ndash; Granulomatosis with polyangiitis (Wegener&rsquo;s), eosinophilic granulomatosis with polyangiitis (Churg-Strauss), and pulmonary lymphomatoid granulomatosis can be differentiated from sarcoidosis by their angiocentric pattern and associated evidence of vasculitis. Measurement of a serum antineutrophil cytoplasmic antibody test (ANCA) may be helpful in identifying systemic vasculitis. (See <a href=\"topic.htm?path=respiratory-tract-involvement-in-granulomatosis-with-polyangiitis-and-microscopic-polyangiitis\" class=\"medical medical_review\">&quot;Respiratory tract involvement in granulomatosis with polyangiitis and microscopic polyangiitis&quot;</a> and <a href=\"topic.htm?path=clinical-features-and-diagnosis-of-eosinophilic-granulomatosis-with-polyangiitis-churg-strauss\" class=\"medical medical_review\">&quot;Clinical features and diagnosis of eosinophilic granulomatosis with polyangiitis (Churg-Strauss)&quot;</a> and <a href=\"topic.htm?path=pulmonary-lymphomatoid-granulomatosis\" class=\"medical medical_review\">&quot;Pulmonary lymphomatoid granulomatosis&quot;</a>.) </p><p/><p class=\"bulletIndent1\"><span class=\"glyph\">&#9679;</span>Bronchocentric granulomatosis &ndash; Bronchocentric granulomatosis is characterized by peribronchial and peribronchiolar necrotizing granulomatous inflammation. Approximately half of all cases are associated with asthma and allergic bronchopulmonary aspergillosis. (See <a href=\"topic.htm?path=bronchocentric-granulomatosis\" class=\"medical medical_review\">&quot;Bronchocentric granulomatosis&quot;</a>.)</p><p/><p class=\"bulletIndent1\"><span class=\"glyph\">&#9679;</span>Primary immunodeficiencies &ndash; Patients with chronic granulomatous disease typically develop granulomas in response to infectious agents, but can develop noninfectious pulmonary granulomas. A sarcoid-like disorder with granulomatous infiltration of the liver and lungs and variable elevations in ACE levels is recognized in patients with common variable immunodeficiency (CVID). Therefore, patients with apparent sarcoidosis who are hypogammaglobulinemic and have recurrent infections should be evaluated for CVID. These disorders are discussed separately. (See <a href=\"topic.htm?path=pulmonary-complications-of-primary-immunodeficiencies#H1323800\" class=\"medical medical_review\">&quot;Pulmonary complications of primary immunodeficiencies&quot;, section on 'Chronic granulomatous disease'</a> and <a href=\"topic.htm?path=pulmonary-complications-of-primary-immunodeficiencies#H7222843\" class=\"medical medical_review\">&quot;Pulmonary complications of primary immunodeficiencies&quot;, section on 'Severe combined immunodeficiency'</a>.)</p><p/><p class=\"bulletIndent1\"><span class=\"glyph\">&#9679;</span>Immune reconstitution inflammatory syndrome (IRIS) &ndash; The occurrence of sarcoidosis several months after initiation of potent combination antiretroviral therapy (ART) suggests that immune reconstitution may &quot;trigger&quot; the reactivation or appearance of preexisting subclinical sarcoidosis. Indeed some but not all patients with IRIS-associated sarcoidosis had preexisting known sarcoidosis that became inactive years earlier. (See <a href=\"topic.htm?path=immune-reconstitution-inflammatory-syndrome#H18\" class=\"medical medical_review\">&quot;Immune reconstitution inflammatory syndrome&quot;, section on 'Miscellaneous syndromes possibly associated with IRIS'</a>.)</p><p/><p class=\"headingAnchor\" id=\"H272445441\"><span class=\"h1\">INITIAL ASSESSMENT OF DISEASE EXTENT</span><span class=\"headingEndMark\">&#160;&#8212;&#160;</span>Once the diagnosis of pulmonary sarcoidosis is confirmed, the extent of involvement of other organs should be determined. For patients with biopsy-proven sarcoidosis in one organ and no evidence of an alternative diagnosis, an instrument exists which can serve as a surrogate for tissue confirmation of sarcoidosis involving other organs (<a href=\"image.htm?imageKey=PULM%2F65081%7EPULM%2F72769\" class=\"graphic graphic_table graphicRef65081 graphicRef72769 \">table 3A-B</a>) [<a href=\"https://www.uptodate.com/contents/clinical-manifestations-and-diagnosis-of-pulmonary-sarcoidosis/abstract/98\" class=\"abstract_t\">98</a>]. The extrapulmonary organ systems that may be affected by sarcoidosis are described separately. (See <a href=\"topic.htm?path=extrapulmonary-manifestations-of-sarcoidosis\" class=\"medical medical_review\">&quot;Extrapulmonary manifestations of sarcoidosis&quot;</a>.)</p><p>In addition to clinical and laboratory assessment for extrapulmonary sarcoidosis, all patients with a new diagnosis of sarcoid should have an electrocardiogram. Additional studies, such as 24 hour Holter monitoring and echocardiography, are performed based on symptoms, signs, and results of the electrocardiogram. These patients should also undergo visual acuity, tonometry, slit lamp, and fundoscopic testing to assess for ocular involvement. (See <a href=\"topic.htm?path=clinical-manifestations-and-diagnosis-of-cardiac-sarcoidosis\" class=\"medical medical_review\">&quot;Clinical manifestations and diagnosis of cardiac sarcoidosis&quot;</a> and <a href=\"topic.htm?path=extrapulmonary-manifestations-of-sarcoidosis#H18586377\" class=\"medical medical_review\">&quot;Extrapulmonary manifestations of sarcoidosis&quot;, section on 'Ocular'</a>.)</p><p>In addition to assessing extrapulmonary organ involvement, we obtain serum testing for vitamin D deficiency by measuring both 25-hydroxyvitamin D (calcidiol) and 1,25-dihydroxyvitamin D (<a href=\"image.htm?imageKey=ENDO%2F65360\" class=\"graphic graphic_figure graphicRef65360 \">figure 1</a>) [<a href=\"https://www.uptodate.com/contents/clinical-manifestations-and-diagnosis-of-pulmonary-sarcoidosis/abstract/99\" class=\"abstract_t\">99</a>]. Deficiency of 25-hydroxyvitamin D is nearly universal among patients with sarcoidosis, although 1,25-dihydroxyvitamin D is sufficient in 70 percent. The cause of low levels of 25-hydroxyvitamin D in sarcoidosis is not known. (See <a href=\"topic.htm?path=overview-of-vitamin-d\" class=\"medical medical_review\">&quot;Overview of vitamin D&quot;</a>.)</p><p>As hypercalciuria is common, we obtain a spot urine for calcium and creatinine. For patients with an elevated serum calcium, a 24 hour urine is obtained to assess urinary calcium excretion and creatinine clearance. If the urinalysis shows protein, then urinary protein is also assessed in the 24 hour specimen. (See <a href=\"topic.htm?path=renal-disease-in-sarcoidosis\" class=\"medical medical_review\">&quot;Renal disease in sarcoidosis&quot;</a>.)</p><p class=\"headingAnchor\" id=\"H41\"><span class=\"h1\">MONITORING</span><span class=\"headingEndMark\">&#160;&#8212;&#160;</span>There are no data on the indications for specific tests and optimal frequency of monitoring of disease activity in sarcoidosis [<a href=\"https://www.uptodate.com/contents/clinical-manifestations-and-diagnosis-of-pulmonary-sarcoidosis/abstract/100\" class=\"abstract_t\">100</a>]. Patients with more significant initial symptoms will need more frequent follow up, those who have minimal or no symptoms need less frequent evaluation. For example, patients who are started on <a href=\"topic.htm?path=prednisone-drug-information\" class=\"drug drug_general\">prednisone</a> for active disease will need to be reevaluated in four to eight-week intervals, but patients who are asymptomatic may be seen in three to four-month intervals for the first year and less frequently (usually yearly) thereafter. Routine monitoring of sarcoidosis also includes evaluation for the types of extrapulmonary involvement that can lead to organ or life-threatening disease, although the validity of such monitoring has not been formally assessed. A general guideline and list of tests is provided in the table (<a href=\"image.htm?imageKey=PULM%2F67386\" class=\"graphic graphic_table graphicRef67386 \">table 4</a>).</p><p>Any new symptoms and on-going medications used to treat active disease will also influence follow up testing. (See <a href=\"topic.htm?path=treatment-of-pulmonary-sarcoidosis-disease-refractory-to-glucocorticoid-therapy\" class=\"medical medical_review\">&quot;Treatment of pulmonary sarcoidosis: Disease refractory to glucocorticoid therapy&quot;</a> and <a href=\"topic.htm?path=treatment-of-pulmonary-sarcoidosis-initial-therapy-with-glucocorticoids\" class=\"medical medical_review\">&quot;Treatment of pulmonary sarcoidosis: Initial therapy with glucocorticoids&quot;</a> and <a href=\"topic.htm?path=extrapulmonary-manifestations-of-sarcoidosis#H18586365\" class=\"medical medical_review\">&quot;Extrapulmonary manifestations of sarcoidosis&quot;, section on 'Diagnostic approach'</a>.)</p><p class=\"headingAnchor\" id=\"H3170426885\"><span class=\"h1\">COMPLICATIONS</span><span class=\"headingEndMark\">&#160;&#8212;&#160;</span>Pulmonary sarcoidosis is occasionally associated with complications such as venous thromboembolic disease (VTE), development of aspergilloma, and pulmonary hypertension.</p><p>An increased risk of VTE has been reported in patients with sarcoidosis. In a population-based study of 345 incident cases of sarcoidosis and 345 sex, age, and calendar year-matched comparator subjects, an increased risk was noted among patients with sarcoidosis (HR 3.04, 95% CI 1.47-7.48) and (HR 4.29, 95% CI 1.21-15.23) for deep venous thrombosis and pulmonary embolism, respectively [<a href=\"https://www.uptodate.com/contents/clinical-manifestations-and-diagnosis-of-pulmonary-sarcoidosis/abstract/101\" class=\"abstract_t\">101</a>]. This observation was supported by an analysis of the Explorys, IBM Watson Health data set with more than 20 million patients of whom more than 53 thousand had a diagnosis of sarcoidosis [<a href=\"https://www.uptodate.com/contents/clinical-manifestations-and-diagnosis-of-pulmonary-sarcoidosis/abstract/102\" class=\"abstract_t\">102</a>]. After adjusting for sex, age, and race, the odds ratio was 3.06 (95% CI 2.94-3.18) for DVT and 3.96 (95% CI 3.80-4.13) for PE. </p><p>Chronic pulmonary aspergillosis (CPA) complicates approximately 2 percent of sarcoidosis, most commonly presenting as an aspergilloma in fibrocystic sarcoidosis [<a href=\"https://www.uptodate.com/contents/clinical-manifestations-and-diagnosis-of-pulmonary-sarcoidosis/abstract/103,104\" class=\"abstract_t\">103,104</a>]. Aspergillomas can also complicate cavitary sarcoidosis [<a href=\"https://www.uptodate.com/contents/clinical-manifestations-and-diagnosis-of-pulmonary-sarcoidosis/abstract/41,105\" class=\"abstract_t\">41,105</a>]. The diagnosis and treatment of aspergilloma are described separately. (See <a href=\"topic.htm?path=clinical-manifestations-and-diagnosis-of-chronic-pulmonary-aspergillosis#H19\" class=\"medical medical_review\">&quot;Clinical manifestations and diagnosis of chronic pulmonary aspergillosis&quot;, section on 'Aspergilloma'</a> and <a href=\"topic.htm?path=treatment-of-chronic-pulmonary-aspergillosis#H8\" class=\"medical medical_review\">&quot;Treatment of chronic pulmonary aspergillosis&quot;, section on 'Aspergilloma'</a>.)</p><p>In patients with sarcoidosis, pulmonary hypertension is generally a complication of advanced lung fibrosis. Pulmonary hypertension correlates with the need for supplemental oxygen, but not spirometric results. The evaluation and management of pulmonary fibrosis due to lung disease are discussed separately. (See <a href=\"topic.htm?path=pulmonary-hypertension-due-to-lung-disease-and-or-hypoxemia-group-3-pulmonary-hypertension-epidemiology-pathogenesis-and-diagnostic-evaluation-in-adults\" class=\"medical medical_review\">&quot;Pulmonary hypertension due to lung disease and/or hypoxemia (group 3 pulmonary hypertension): Epidemiology, pathogenesis, and diagnostic evaluation in adults&quot;</a> and <a href=\"topic.htm?path=pulmonary-hypertension-due-to-lung-disease-and-or-hypoxemia-group-3-pulmonary-hypertension-treatment-and-prognosis\" class=\"medical medical_review\">&quot;Pulmonary hypertension due to lung disease and/or hypoxemia (group 3 pulmonary hypertension): Treatment and prognosis&quot;</a>.)</p><p class=\"headingAnchor\" id=\"H1163815402\"><span class=\"h1\">SOCIETY GUIDELINE LINKS</span><span class=\"headingEndMark\">&#160;&#8212;&#160;</span>Links to society and government-sponsored guidelines from selected countries and regions around the world are provided separately. (See <a href=\"topic.htm?path=society-guideline-links-sarcoidosis\" class=\"medical medical_society_guidelines\">&quot;Society guideline links: Sarcoidosis&quot;</a>.)</p><p class=\"headingAnchor\" id=\"PATIENT_INFORMATION\"><span class=\"h1\">INFORMATION FOR PATIENTS</span><span class=\"headingEndMark\">&#160;&#8212;&#160;</span>UpToDate offers two types of patient education materials, &ldquo;The Basics&rdquo; and &ldquo;Beyond the Basics.&rdquo; The Basics patient education pieces are written in plain language, at the 5<sup>th</sup> to 6<sup>th</sup> grade reading level, and they answer the four or five key questions a patient might have about a given condition. These articles are best for patients who want a general overview and who prefer short, easy-to-read materials. Beyond the Basics patient education pieces are longer, more sophisticated, and more detailed. These articles are written at the 10<sup>th</sup> to 12<sup>th</sup> grade reading level and are best for patients who want in-depth information and are comfortable with some medical jargon.</p><p>Here are the patient education articles that are relevant to this topic. We encourage you to print or e-mail these topics to your patients. (You can also locate patient education articles on a variety of subjects by searching on &ldquo;patient info&rdquo; and the keyword(s) of interest.) </p><p class=\"bulletIndent1\"><span class=\"glyph\">&#9679;</span>Basics topics (see <a href=\"topic.htm?path=sarcoidosis-the-basics\" class=\"medical medical_basics\">&quot;Patient education: Sarcoidosis (The Basics)&quot;</a>)</p><p/><p class=\"bulletIndent1\"><span class=\"glyph\">&#9679;</span>Beyond the Basics topics (see <a href=\"topic.htm?path=sarcoidosis-beyond-the-basics\" class=\"medical medical_patient\">&quot;Patient education: Sarcoidosis (Beyond the Basics)&quot;</a>)</p><p/><p class=\"headingAnchor\" id=\"H43\"><span class=\"h1\">SUMMARY AND RECOMMENDATIONS</span></p><p class=\"bulletIndent1\"><span class=\"glyph\">&#9679;</span>Sarcoidosis is a multisystem disorder of unknown etiology that is characterized pathologically by the presence of noncaseating granulomas in involved organs. (See <a href=\"#H1\" class=\"local\">'Introduction'</a> above and <a href=\"#H3\" class=\"local\">'Etiology'</a> above and <a href=\"topic.htm?path=extrapulmonary-manifestations-of-sarcoidosis#H18587448\" class=\"medical medical_review\">&quot;Extrapulmonary manifestations of sarcoidosis&quot;, section on 'Introduction'</a>.)</p><p/><p class=\"bulletIndent1\"><span class=\"glyph\">&#9679;</span>The estimated prevalence of sarcoidosis is 10 to 20 per 100,000 population. Sarcoidosis is more common among blacks than whites. Blacks more commonly present with acute, severe disease, while whites more commonly present with mild, chronic disease. (See <a href=\"#H2\" class=\"local\">'Epidemiology'</a> above.)</p><p/><p class=\"bulletIndent1\"><span class=\"glyph\">&#9679;</span>Sarcoidosis typically affects young adults. In approximately one-half of cases, it is detected in asymptomatic individuals due to incidental radiographic abnormalities (eg, bilateral hilar adenopathy, reticular opacities). Common presenting symptoms include cough, dyspnea, chest pain, eye lesions, <span class=\"nowrap\">and/or</span> skin lesions. Other extrapulmonary manifestations are listed in the table (<a href=\"image.htm?imageKey=PULM%2F76046\" class=\"graphic graphic_table graphicRef76046 \">table 1</a>). (See <a href=\"#H4\" class=\"local\">'Clinical manifestations'</a> above.)</p><p/><p class=\"bulletIndent1\"><span class=\"glyph\">&#9679;</span>A comprehensive evaluation should be performed in all patients with suspected sarcoidosis, including history, physical examination, a chest radiograph, pulmonary function tests, peripheral blood counts, serum chemistries, urinalysis, electrocardiogram, ophthalmologic examination, and a <a href=\"topic.htm?path=tuberculin-skin-test-drug-information\" class=\"drug drug_general\">tuberculin skin test</a>. The purpose of this evaluation is to obtain additional data supporting the diagnosis of sarcoidosis and to assess disease severity and extent, while eliminating alternative diagnoses. (See <a href=\"#H3513219\" class=\"local\">'Evaluation'</a> above.)</p><p/><p class=\"bulletIndent1\"><span class=\"glyph\">&#9679;</span>Pulmonary imaging plays an essential role in the diagnosis of sarcoidosis, starting with a chest radiograph, which is often followed by high resolution computed tomography. Other imaging tests, such as fluorine-18-fluorodeoxyglucose-positron emission tomography (FDG-PET) and other radiotracer scans are used on a case-by-case basis. The &quot;classic&quot; chest radiograph reveals bilateral hilar adenopathy. This finding, however, may be absent or, if present, may occur in combination with parenchymal opacities. (See <a href=\"#H7\" class=\"local\">'Pulmonary imaging'</a> above.)</p><p/><p class=\"bulletIndent1\"><span class=\"glyph\">&#9679;</span>Pulmonary function tests (spirometry, lung volumes, diffusing capacity, and six-minute walk test) are obtained in all patients with suspected sarcoidosis to assess for respiratory impairment and characteristically demonstrate a restrictive defect with reduced gas exchange and reduced functional status. (See <a href=\"#H34\" class=\"local\">'Pulmonary function testing'</a> above.)</p><p/><p class=\"bulletIndent1\"><span class=\"glyph\">&#9679;</span>The diagnosis of sarcoidosis requires compatible clinical and radiographic manifestations, exclusion of other diseases that may present similarly, and histopathologic detection of noncaseating granulomas. Patients who present with asymptomatic bilateral hilar adenopathy or a classical Lofgren syndrome of fever, erythema nodosum, arthralgias, and bilateral hilar lymphadenopathy do not require biopsy if the abnormalities resolve quickly and spontaneously. (See <a href=\"#H37\" class=\"local\">'Diagnostic approach'</a> above.)</p><p/><p class=\"bulletIndent1\"><span class=\"glyph\">&#9679;</span>Biopsy should be performed in most cases of suspected sarcoidosis. Biopsy of accessible peripheral lesions (eg, cutaneous lesions, palpable lymph nodes, conjunctival lesions) is preferred to an invasive procedure. If an accessible lesion cannot be identified, the choice of procedure depends on the pattern and location of lung parenchymal abnormalities, the presence and location of enlarged thoracic lymph nodes, and also the available expertise and equipment. (See <a href=\"#H272446561\" class=\"local\">'Diagnosis'</a> above.)</p><p/><p class=\"bulletIndent1\"><span class=\"glyph\">&#9679;</span>If ultrasound-guided endoscopy or flexible bronchoscopy cannot be performed or are nondiagnostic, the next step is usually surgical mediastinal lymph node biopsy, followed by surgical lung biopsy via thoracoscopy or thoracotomy. (See <a href=\"#H272446222\" class=\"local\">'Surgical biopsy of mediastinum and lung'</a> above.)</p><p/><p class=\"bulletIndent1\"><span class=\"glyph\">&#9679;</span>Noncaseating granulomas are the characteristic histopathologic abnormality in sarcoidosis. The differential diagnosis of granulomatous lung diseases includes many conditions; it is particularly important to exclude infections and malignancy. (See <a href=\"#H272446686\" class=\"local\">'Histopathology'</a> above and <a href=\"#H37\" class=\"local\">'Diagnostic approach'</a> above.)</p><p/></div><div id=\"topicAgreement\">Use of UpToDate is subject to the <a href=\"https://www.uptodate.com/legal/license\" class=\"licenseLink\" id=\"sla_in_page\">Subscription and License Agreement</a>.</div><div id=\"references\" class=\"headingAnchor\"><h1>REFERENCES</h1><ol id=\"reference\"><li><a href=\"https://www.uptodate.com/contents/clinical-manifestations-and-diagnosis-of-pulmonary-sarcoidosis/abstract/1\" class=\"nounderline abstract_t\">Thomas KW, Hunninghake GW. Sarcoidosis. JAMA 2003; 289:3300.</a></li><li><a href=\"https://www.uptodate.com/contents/clinical-manifestations-and-diagnosis-of-pulmonary-sarcoidosis/abstract/2\" class=\"nounderline abstract_t\">Rybicki BA, Major M, Popovich J Jr, et al. Racial differences in sarcoidosis incidence: a 5-year study in a health maintenance organization. Am J Epidemiol 1997; 145:234.</a></li><li><a href=\"https://www.uptodate.com/contents/clinical-manifestations-and-diagnosis-of-pulmonary-sarcoidosis/abstract/3\" class=\"nounderline abstract_t\">Dumas O, Abramovitz L, Wiley AS, et al. Epidemiology of Sarcoidosis in a Prospective Cohort Study of U.S. Women. Ann Am Thorac Soc 2016; 13:67.</a></li><li><a href=\"https://www.uptodate.com/contents/clinical-manifestations-and-diagnosis-of-pulmonary-sarcoidosis/abstract/4\" class=\"nounderline abstract_t\">Ungprasert P, Carmona EM, Utz JP, et al. Epidemiology of Sarcoidosis 1946-2013: A Population-Based Study. Mayo Clin Proc 2016; 91:183.</a></li><li><a href=\"https://www.uptodate.com/contents/clinical-manifestations-and-diagnosis-of-pulmonary-sarcoidosis/abstract/5\" class=\"nounderline abstract_t\">Ungprasert P, Crowson CS, Matteson EL. Influence of Gender on Epidemiology and Clinical Manifestations of Sarcoidosis: A Population-Based Retrospective Cohort Study 1976-2013. Lung 2017; 195:87.</a></li><li><a href=\"https://www.uptodate.com/contents/clinical-manifestations-and-diagnosis-of-pulmonary-sarcoidosis/abstract/6\" class=\"nounderline abstract_t\">Ungprasert P, Crowson CS, Achenbach SJ, et al. Hospitalization Among Patients with Sarcoidosis: A Population-Based Cohort Study 1987-2015. Lung 2017; 195:411.</a></li><li><a href=\"https://www.uptodate.com/contents/clinical-manifestations-and-diagnosis-of-pulmonary-sarcoidosis/abstract/7\" class=\"nounderline abstract_t\">Baughman RP, Lower EE, du Bois RM. Sarcoidosis. Lancet 2003; 361:1111.</a></li><li><a href=\"https://www.uptodate.com/contents/clinical-manifestations-and-diagnosis-of-pulmonary-sarcoidosis/abstract/8\" class=\"nounderline abstract_t\">Martinetti M, Tinelli C, Kolek V, et al. &quot;The sarcoidosis map&quot;: a joint survey of clinical and immunogenetic findings in two European countries. Am J Respir Crit Care Med 1995; 152:557.</a></li><li><a href=\"https://www.uptodate.com/contents/clinical-manifestations-and-diagnosis-of-pulmonary-sarcoidosis/abstract/9\" class=\"nounderline abstract_t\">Newman LS, Rose CS, Maier LA. Sarcoidosis. N Engl J Med 1997; 336:1224.</a></li><li><a href=\"https://www.uptodate.com/contents/clinical-manifestations-and-diagnosis-of-pulmonary-sarcoidosis/abstract/10\" class=\"nounderline abstract_t\">Morimoto T, Azuma A, Abe S, et al. Epidemiology of sarcoidosis in Japan. Eur Respir J 2008; 31:372.</a></li><li><a href=\"https://www.uptodate.com/contents/clinical-manifestations-and-diagnosis-of-pulmonary-sarcoidosis/abstract/11\" class=\"nounderline abstract_t\">Johnson LA, Edsall JR, Austin JH, Ellis K. Pulmonary sarcoidosis: could mycoplasma-like organisms be a cause? Sarcoidosis Vasc Diffuse Lung Dis 1996; 13:38.</a></li><li><a href=\"https://www.uptodate.com/contents/clinical-manifestations-and-diagnosis-of-pulmonary-sarcoidosis/abstract/12\" class=\"nounderline abstract_t\">Bocart D, Lecossier D, De Lassence A, et al. A search for mycobacterial DNA in granulomatous tissues from patients with sarcoidosis using the polymerase chain reaction. Am Rev Respir Dis 1992; 145:1142.</a></li><li><a href=\"https://www.uptodate.com/contents/clinical-manifestations-and-diagnosis-of-pulmonary-sarcoidosis/abstract/13\" class=\"nounderline abstract_t\">Rybicki BA, Iannuzzi MC, Frederick MM, et al. Familial aggregation of sarcoidosis. A case-control etiologic study of sarcoidosis (ACCESS). Am J Respir Crit Care Med 2001; 164:2085.</a></li><li><a href=\"https://www.uptodate.com/contents/clinical-manifestations-and-diagnosis-of-pulmonary-sarcoidosis/abstract/14\" class=\"nounderline abstract_t\">Judson MA, Boan AD, Lackland DT. The clinical course of sarcoidosis: presentation, diagnosis, and treatment in a large white and black cohort in the United States. Sarcoidosis Vasc Diffuse Lung Dis 2012; 29:119.</a></li><li><a href=\"https://www.uptodate.com/contents/clinical-manifestations-and-diagnosis-of-pulmonary-sarcoidosis/abstract/15\" class=\"nounderline abstract_t\">Baughman RP, Teirstein AS, Judson MA, et al. Clinical characteristics of patients in a case control study of sarcoidosis. Am J Respir Crit Care Med 2001; 164:1885.</a></li><li><a href=\"https://www.uptodate.com/contents/clinical-manifestations-and-diagnosis-of-pulmonary-sarcoidosis/abstract/16\" class=\"nounderline abstract_t\">Rizzato G, Tinelli C. Unusual presentation of sarcoidosis. Respiration 2005; 72:3.</a></li><li><a href=\"https://www.uptodate.com/contents/clinical-manifestations-and-diagnosis-of-pulmonary-sarcoidosis/abstract/17\" class=\"nounderline abstract_t\">Rizzato G, Palmieri G, Agrati AM, Zanussi C. The organ-specific extrapulmonary presentation of sarcoidosis: a frequent occurrence but a challenge to an early diagnosis. A 3-year-long prospective observational study. Sarcoidosis Vasc Diffuse Lung Dis 2004; 21:119.</a></li><li><a href=\"https://www.uptodate.com/contents/clinical-manifestations-and-diagnosis-of-pulmonary-sarcoidosis/abstract/18\" class=\"nounderline abstract_t\">Sharma OP. Fatigue and sarcoidosis. Eur Respir J 1999; 13:713.</a></li><li><a href=\"https://www.uptodate.com/contents/clinical-manifestations-and-diagnosis-of-pulmonary-sarcoidosis/abstract/19\" class=\"nounderline abstract_t\">Chevalet P, Cl&eacute;ment R, Rodat O, et al. Sarcoidosis diagnosed in elderly subjects: retrospective study of 30 cases. Chest 2004; 126:1423.</a></li><li><a href=\"https://www.uptodate.com/contents/clinical-manifestations-and-diagnosis-of-pulmonary-sarcoidosis/abstract/20\" class=\"nounderline abstract_t\">Spruit MA, Thomeer MJ, Gosselink R, et al. Skeletal muscle weakness in patients with sarcoidosis and its relationship with exercise intolerance and reduced health status. Thorax 2005; 60:32.</a></li><li><a href=\"https://www.uptodate.com/contents/clinical-manifestations-and-diagnosis-of-pulmonary-sarcoidosis/abstract/21\" class=\"nounderline abstract_t\">Delobbe A, Perrault H, Maitre J, et al. Impaired exercise response in sarcoid patients with normal pulmonary functio. Sarcoidosis Vasc Diffuse Lung Dis 2002; 19:148.</a></li><li><a href=\"https://www.uptodate.com/contents/clinical-manifestations-and-diagnosis-of-pulmonary-sarcoidosis/abstract/22\" class=\"nounderline abstract_t\">Miller A, Brown LK, Sloane MF, et al. Cardiorespiratory responses to incremental exercise in sarcoidosis patients with normal spirometry. Chest 1995; 107:323.</a></li><li><a href=\"https://www.uptodate.com/contents/clinical-manifestations-and-diagnosis-of-pulmonary-sarcoidosis/abstract/23\" class=\"nounderline abstract_t\">Nathan N, Marcelo P, Houdouin V, et al. Lung sarcoidosis in children: update on disease expression and management. Thorax 2015; 70:537.</a></li><li><a href=\"https://www.uptodate.com/contents/clinical-manifestations-and-diagnosis-of-pulmonary-sarcoidosis/abstract/24\" class=\"nounderline abstract_t\">Pattishall EN, Kendig EL Jr. Sarcoidosis in children. Pediatr Pulmonol 1996; 22:195.</a></li><li><a href=\"https://www.uptodate.com/contents/clinical-manifestations-and-diagnosis-of-pulmonary-sarcoidosis/abstract/25\" class=\"nounderline abstract_t\">Milman N, Hoffmann AL. Childhood sarcoidosis: long-term follow-up. Eur Respir J 2008; 31:592.</a></li><li><a href=\"https://www.uptodate.com/contents/clinical-manifestations-and-diagnosis-of-pulmonary-sarcoidosis/abstract/26\" class=\"nounderline abstract_t\">Statement on sarcoidosis. Joint Statement of the American Thoracic Society (ATS), the European Respiratory Society (ERS) and the World Association of Sarcoidosis and Other Granulomatous Disorders (WASOG) adopted by the ATS Board of Directors and by the ERS Executive Committee, February 1999. Am J Respir Crit Care Med 1999; 160:736.</a></li><li><a href=\"https://www.uptodate.com/contents/clinical-manifestations-and-diagnosis-of-pulmonary-sarcoidosis/abstract/27\" class=\"nounderline abstract_t\">Judson MA. The diagnosis of sarcoidosis. Clin Chest Med 2008; 29:415.</a></li><li><a href=\"https://www.uptodate.com/contents/clinical-manifestations-and-diagnosis-of-pulmonary-sarcoidosis/abstract/28\" class=\"nounderline abstract_t\">de Prost N, Kerrou K, Sibony M, et al. Fluorine-18 fluorodeoxyglucose with positron emission tomography revealed bone marrow involvement in sarcoidosis patients with anaemia. Respiration 2010; 79:25.</a></li><li><a href=\"https://www.uptodate.com/contents/clinical-manifestations-and-diagnosis-of-pulmonary-sarcoidosis/abstract/29\" class=\"nounderline abstract_t\">Lower EE, Smith JT, Martelo OJ, Baughman RP. The anemia of sarcoidosis. Sarcoidosis 1988; 5:51.</a></li><li><a href=\"https://www.uptodate.com/contents/clinical-manifestations-and-diagnosis-of-pulmonary-sarcoidosis/abstract/30\" class=\"nounderline abstract_t\">Yanarda&#287; H, Pamuk GE, Karayel T, Demirci S. Bone marrow involvement in sarcoidosis: an analysis of 50 bone marrow samples. Haematologia (Budap) 2002; 32:419.</a></li><li><a href=\"https://www.uptodate.com/contents/clinical-manifestations-and-diagnosis-of-pulmonary-sarcoidosis/abstract/31\" class=\"nounderline abstract_t\">Renston JP, Goldman ES, Hsu RM, Tomashefski JF Jr. Peripheral blood eosinophilia in association with sarcoidosis. Mayo Clin Proc 2000; 75:586.</a></li><li class=\"breakAll\">Spagnolo P, Cullinan P, duBois RM. Sarcoidosis. In: Interstitial Lung Disease, 5th, Schwarz MI, King TE Jr (Eds), People's Medical Publishing House, Shelton, CT 2011. p.433.</li><li><a href=\"https://www.uptodate.com/contents/clinical-manifestations-and-diagnosis-of-pulmonary-sarcoidosis/abstract/33\" class=\"nounderline abstract_t\">Marcellis RG, Lenssen AF, Elfferich MD, et al. Exercise capacity, muscle strength and fatigue in sarcoidosis. Eur Respir J 2011; 38:628.</a></li><li><a href=\"https://www.uptodate.com/contents/clinical-manifestations-and-diagnosis-of-pulmonary-sarcoidosis/abstract/34\" class=\"nounderline abstract_t\">Sweiss NJ, Barnathan ES, Lo K, et al. C-reactive protein predicts response to infliximab in patients with chronic sarcoidosis. Sarcoidosis Vasc Diffuse Lung Dis 2010; 27:49.</a></li><li><a href=\"https://www.uptodate.com/contents/clinical-manifestations-and-diagnosis-of-pulmonary-sarcoidosis/abstract/35\" class=\"nounderline abstract_t\">Gungor S, Ozseker F, Yalcinsoy M, et al. Conventional markers in determination of activity of sarcoidosis. Int Immunopharmacol 2015; 25:174.</a></li><li><a href=\"https://www.uptodate.com/contents/clinical-manifestations-and-diagnosis-of-pulmonary-sarcoidosis/abstract/36\" class=\"nounderline abstract_t\">Studdy PR, Bird R. Serum angiotensin converting enzyme in sarcoidosis--its value in present clinical practice. Ann Clin Biochem 1989; 26 ( Pt 1):13.</a></li><li><a href=\"https://www.uptodate.com/contents/clinical-manifestations-and-diagnosis-of-pulmonary-sarcoidosis/abstract/37\" class=\"nounderline abstract_t\">Baughman RP. Pulmonary sarcoidosis. Clin Chest Med 2004; 25:521.</a></li><li><a href=\"https://www.uptodate.com/contents/clinical-manifestations-and-diagnosis-of-pulmonary-sarcoidosis/abstract/38\" class=\"nounderline abstract_t\">Ungprasert P, Carmona EM, Crowson CS, Matteson EL. Diagnostic Utility of Angiotensin-Converting Enzyme in Sarcoidosis: A Population-Based Study. Lung 2016; 194:91.</a></li><li><a href=\"https://www.uptodate.com/contents/clinical-manifestations-and-diagnosis-of-pulmonary-sarcoidosis/abstract/39\" class=\"nounderline abstract_t\">Grutters JC, Fellrath JM, Mulder L, et al. Serum soluble interleukin-2 receptor measurement in patients with sarcoidosis: a clinical evaluation. Chest 2003; 124:186.</a></li><li class=\"breakAll\">Semenzato C, Facco M, Agostini C. Immunologic events in the pathogenesis of interstitial lung disease: the paradigm of sarcoidosis. In: Interstitial Lung Disease, 5th, Schwarz, MI, King, TE JR (Eds), People's Medical Publishing House, Shelton, CT 2011. p.407.</li><li><a href=\"https://www.uptodate.com/contents/clinical-manifestations-and-diagnosis-of-pulmonary-sarcoidosis/abstract/41\" class=\"nounderline abstract_t\">Hours S, Nunes H, Kambouchner M, et al. Pulmonary cavitary sarcoidosis: clinico-radiologic characteristics and natural history of a rare form of sarcoidosis. Medicine (Baltimore) 2008; 87:142.</a></li><li><a href=\"https://www.uptodate.com/contents/clinical-manifestations-and-diagnosis-of-pulmonary-sarcoidosis/abstract/42\" class=\"nounderline abstract_t\">Soskel NT, Sharma OP. Pleural involvement in sarcoidosis. Curr Opin Pulm Med 2000; 6:455.</a></li><li><a href=\"https://www.uptodate.com/contents/clinical-manifestations-and-diagnosis-of-pulmonary-sarcoidosis/abstract/43\" class=\"nounderline abstract_t\">Navaneethan SD, Venkatesh S, Shrivastava R, et al. Recurrent pleural and pericardial effusions due to sarcoidosis. PLoS Med 2005; 2:e63.</a></li><li><a href=\"https://www.uptodate.com/contents/clinical-manifestations-and-diagnosis-of-pulmonary-sarcoidosis/abstract/44\" class=\"nounderline abstract_t\">Huggins JT, Doelken P, Sahn SA, et al. Pleural effusions in a series of 181 outpatients with sarcoidosis. Chest 2006; 129:1599.</a></li><li><a href=\"https://www.uptodate.com/contents/clinical-manifestations-and-diagnosis-of-pulmonary-sarcoidosis/abstract/45\" class=\"nounderline abstract_t\">Koyama T, Ueda H, Togashi K, et al. Radiologic manifestations of sarcoidosis in various organs. Radiographics 2004; 24:87.</a></li><li><a href=\"https://www.uptodate.com/contents/clinical-manifestations-and-diagnosis-of-pulmonary-sarcoidosis/abstract/46\" class=\"nounderline abstract_t\">Malaisamy S, Dalal B, Bimenyuy C, Soubani AO. The clinical and radiologic features of nodular pulmonary sarcoidosis. Lung 2009; 187:9.</a></li><li><a href=\"https://www.uptodate.com/contents/clinical-manifestations-and-diagnosis-of-pulmonary-sarcoidosis/abstract/47\" class=\"nounderline abstract_t\">Sileo C, Epaud R, Mahloul M, et al. Sarcoidosis in children: HRCT findings and correlation with pulmonary function tests. Pediatr Pulmonol 2014; 49:1223.</a></li><li><a href=\"https://www.uptodate.com/contents/clinical-manifestations-and-diagnosis-of-pulmonary-sarcoidosis/abstract/48\" class=\"nounderline abstract_t\">Nishimura K, Itoh H, Kitaichi M, et al. Pulmonary sarcoidosis: correlation of CT and histopathologic findings. Radiology 1993; 189:105.</a></li><li><a href=\"https://www.uptodate.com/contents/clinical-manifestations-and-diagnosis-of-pulmonary-sarcoidosis/abstract/49\" class=\"nounderline abstract_t\">M&uuml;ller NL, Miller RR. Ground-glass attenuation, nodules, alveolitis, and sarcoid granulomas. Radiology 1993; 189:31.</a></li><li><a href=\"https://www.uptodate.com/contents/clinical-manifestations-and-diagnosis-of-pulmonary-sarcoidosis/abstract/50\" class=\"nounderline abstract_t\">Teirstein AS, Machac J, Almeida O, et al. Results of 188 whole-body fluorodeoxyglucose positron emission tomography scans in 137 patients with sarcoidosis. Chest 2007; 132:1949.</a></li><li><a href=\"https://www.uptodate.com/contents/clinical-manifestations-and-diagnosis-of-pulmonary-sarcoidosis/abstract/51\" class=\"nounderline abstract_t\">Kaira K, Oriuchi N, Otani Y, et al. Diagnostic usefulness of fluorine-18-alpha-methyltyrosine positron emission tomography in combination with 18F-fluorodeoxyglucose in sarcoidosis patients. Chest 2007; 131:1019.</a></li><li><a href=\"https://www.uptodate.com/contents/clinical-manifestations-and-diagnosis-of-pulmonary-sarcoidosis/abstract/52\" class=\"nounderline abstract_t\">Line BR, Hunninghake GW, Keogh BA, et al. Gallium-67 scanning to stage the alveolitis of sarcoidosis: correlation with clinical studies, pulmonary function studies, and bronchoalveolar lavage. Am Rev Respir Dis 1981; 123:440.</a></li><li><a href=\"https://www.uptodate.com/contents/clinical-manifestations-and-diagnosis-of-pulmonary-sarcoidosis/abstract/53\" class=\"nounderline abstract_t\">Schoenberger CI, Line BR, Keogh BA, et al. Lung inflammation in sarcoidosis: comparison of serum angiotensin-converting enzyme levels with bronchoalveolar lavage and gallium-67 scanning assessment of the T lymphocyte alveolitis. Thorax 1982; 37:19.</a></li><li><a href=\"https://www.uptodate.com/contents/clinical-manifestations-and-diagnosis-of-pulmonary-sarcoidosis/abstract/54\" class=\"nounderline abstract_t\">Beaumont D, Herry JY, Sapene M, et al. Gallium-67 in the evaluation of sarcoidosis: correlations with serum angiotensin-converting enzyme and bronchoalveolar lavage. Thorax 1982; 37:11.</a></li><li><a href=\"https://www.uptodate.com/contents/clinical-manifestations-and-diagnosis-of-pulmonary-sarcoidosis/abstract/55\" class=\"nounderline abstract_t\">Baughman RP, Shipley R, Eisentrout CE. Predictive value of gallium scan, angiotensin-converting enzyme level, and bronchoalveolar lavage in two-year follow-up of pulmonary sarcoidosis. Lung 1987; 165:371.</a></li><li><a href=\"https://www.uptodate.com/contents/clinical-manifestations-and-diagnosis-of-pulmonary-sarcoidosis/abstract/56\" class=\"nounderline abstract_t\">Shorr AF, Helman DL, Lettieri CJ, et al. Depreotide scanning in sarcoidosis: a pilot study. Chest 2004; 126:1337.</a></li><li><a href=\"https://www.uptodate.com/contents/clinical-manifestations-and-diagnosis-of-pulmonary-sarcoidosis/abstract/57\" class=\"nounderline abstract_t\">Lebtahi R, Crestani B, Belmatoug N, et al. Somatostatin receptor scintigraphy and gallium scintigraphy in patients with sarcoidosis. J Nucl Med 2001; 42:21.</a></li><li><a href=\"https://www.uptodate.com/contents/clinical-manifestations-and-diagnosis-of-pulmonary-sarcoidosis/abstract/58\" class=\"nounderline abstract_t\">Dunn TL, Watters LC, Hendrix C, et al. Gas exchange at a given degree of volume restriction is different in sarcoidosis and idiopathic pulmonary fibrosis. Am J Med 1988; 85:221.</a></li><li><a href=\"https://www.uptodate.com/contents/clinical-manifestations-and-diagnosis-of-pulmonary-sarcoidosis/abstract/59\" class=\"nounderline abstract_t\">Baughman RP, Sparkman BK, Lower EE. Six-minute walk test and health status assessment in sarcoidosis. Chest 2007; 132:207.</a></li><li><a href=\"https://www.uptodate.com/contents/clinical-manifestations-and-diagnosis-of-pulmonary-sarcoidosis/abstract/60\" class=\"nounderline abstract_t\">Karetzky M, McDonough M. Exercise and resting pulmonary function in sarcoidosis. Sarcoidosis Vasc Diffuse Lung Dis 1996; 13:43.</a></li><li><a href=\"https://www.uptodate.com/contents/clinical-manifestations-and-diagnosis-of-pulmonary-sarcoidosis/abstract/61\" class=\"nounderline abstract_t\">Lin YH, Haslam PL, Turner-Warwick M. Chronic pulmonary sarcoidosis: relationship between lung lavage cell counts, chest radiograph, and results of standard lung function tests. Thorax 1985; 40:501.</a></li><li><a href=\"https://www.uptodate.com/contents/clinical-manifestations-and-diagnosis-of-pulmonary-sarcoidosis/abstract/62\" class=\"nounderline abstract_t\">Ward K, O'Connor C, Odlum C, Fitzgerald MX. Prognostic value of bronchoalveolar lavage in sarcoidosis: the critical influence of disease presentation. Thorax 1989; 44:6.</a></li><li><a href=\"https://www.uptodate.com/contents/clinical-manifestations-and-diagnosis-of-pulmonary-sarcoidosis/abstract/63\" class=\"nounderline abstract_t\">Winterbauer RH, Lammert J, Selland M, et al. Bronchoalveolar lavage cell populations in the diagnosis of sarcoidosis. Chest 1993; 104:352.</a></li><li><a href=\"https://www.uptodate.com/contents/clinical-manifestations-and-diagnosis-of-pulmonary-sarcoidosis/abstract/64\" class=\"nounderline abstract_t\">Agostini C, Trentin L, Zambello R, et al. CD8 alveolitis in sarcoidosis: incidence, phenotypic characteristics, and clinical features. Am J Med 1993; 95:466.</a></li><li><a href=\"https://www.uptodate.com/contents/clinical-manifestations-and-diagnosis-of-pulmonary-sarcoidosis/abstract/65\" class=\"nounderline abstract_t\">Kantrow SP, Meyer KC, Kidd P, Raghu G. The CD4/CD8 ratio in BAL fluid is highly variable in sarcoidosis. Eur Respir J 1997; 10:2716.</a></li><li><a href=\"https://www.uptodate.com/contents/clinical-manifestations-and-diagnosis-of-pulmonary-sarcoidosis/abstract/66\" class=\"nounderline abstract_t\">Perez RL, Duncan A, Hunter RL, Staton GW Jr. Elevated D dimer in the lungs and blood of patients with sarcoidosis. Chest 1993; 103:1100.</a></li><li><a href=\"https://www.uptodate.com/contents/clinical-manifestations-and-diagnosis-of-pulmonary-sarcoidosis/abstract/67\" class=\"nounderline abstract_t\">Perez RL, Kimani AP, King TE Jr, et al. Bronchoalveolar lavage fluid D dimer levels are higher and more prevalent in black patients with pulmonary sarcoidosis. Respiration 2007; 74:297.</a></li><li><a href=\"https://www.uptodate.com/contents/clinical-manifestations-and-diagnosis-of-pulmonary-sarcoidosis/abstract/68\" class=\"nounderline abstract_t\">Meyer KC, Raghu G, Baughman RP, et al. An official American Thoracic Society clinical practice guideline: the clinical utility of bronchoalveolar lavage cellular analysis in interstitial lung disease. Am J Respir Crit Care Med 2012; 185:1004.</a></li><li><a href=\"https://www.uptodate.com/contents/clinical-manifestations-and-diagnosis-of-pulmonary-sarcoidosis/abstract/69\" class=\"nounderline abstract_t\">Polychronopoulos VS, Prakash UBS. Airway involvement in sarcoidosis. Chest 2009; 136:1371.</a></li><li><a href=\"https://www.uptodate.com/contents/clinical-manifestations-and-diagnosis-of-pulmonary-sarcoidosis/abstract/70\" class=\"nounderline abstract_t\">Barreiro TJ. Cobblestone Airways. Mayo Clin Proc 2016; 91:1849.</a></li><li><a href=\"https://www.uptodate.com/contents/clinical-manifestations-and-diagnosis-of-pulmonary-sarcoidosis/abstract/71\" class=\"nounderline abstract_t\">Bradley B, Branley HM, Egan JJ, et al. Interstitial lung disease guideline: the British Thoracic Society in collaboration with the Thoracic Society of Australia and New Zealand and the Irish Thoracic Society. Thorax 2008; 63 Suppl 5:v1.</a></li><li><a href=\"https://www.uptodate.com/contents/clinical-manifestations-and-diagnosis-of-pulmonary-sarcoidosis/abstract/72\" class=\"nounderline abstract_t\">Bjermer L, Thunell M, Rosenhall L, Stjernberg N. Endobronchial biopsy positive sarcoidosis: relation to bronchoalveolar lavage and course of disease. Respir Med 1991; 85:229.</a></li><li><a href=\"https://www.uptodate.com/contents/clinical-manifestations-and-diagnosis-of-pulmonary-sarcoidosis/abstract/73\" class=\"nounderline abstract_t\">de Boer S, Milne DG, Zeng I, Wilsher ML. Does CT scanning predict the likelihood of a positive transbronchial biopsy in sarcoidosis? Thorax 2009; 64:436.</a></li><li><a href=\"https://www.uptodate.com/contents/clinical-manifestations-and-diagnosis-of-pulmonary-sarcoidosis/abstract/74\" class=\"nounderline abstract_t\">Descombes E, Gardiol D, Leuenberger P. Transbronchial lung biopsy: an analysis of 530 cases with reference to the number of samples. Monaldi Arch Chest Dis 1997; 52:324.</a></li><li><a href=\"https://www.uptodate.com/contents/clinical-manifestations-and-diagnosis-of-pulmonary-sarcoidosis/abstract/75\" class=\"nounderline abstract_t\">Roethe RA, Fuller PB, Byrd RB, Hafermann DR. Transbronchoscopic lung biopsy in sarcoidosis. Optimal number and sites for diagnosis. Chest 1980; 77:400.</a></li><li><a href=\"https://www.uptodate.com/contents/clinical-manifestations-and-diagnosis-of-pulmonary-sarcoidosis/abstract/76\" class=\"nounderline abstract_t\">Keogh BA, Hunninghake GW, Line BR, Crystal RG. The alveolitis of pulmonary sarcoidosis. Evaluation of natural history and alveolitis-dependent changes in lung function. Am Rev Respir Dis 1983; 128:256.</a></li><li><a href=\"https://www.uptodate.com/contents/clinical-manifestations-and-diagnosis-of-pulmonary-sarcoidosis/abstract/77\" class=\"nounderline abstract_t\">Takemura T, Hiraga Y, Oomichi M, et al. Ultrastructural features of alveolitis in sarcoidosis. Am J Respir Crit Care Med 1995; 152:360.</a></li><li><a href=\"https://www.uptodate.com/contents/clinical-manifestations-and-diagnosis-of-pulmonary-sarcoidosis/abstract/78\" class=\"nounderline abstract_t\">Ma Y, Gal A, Koss MN. The pathology of pulmonary sarcoidosis: update. Semin Diagn Pathol 2007; 24:150.</a></li><li><a href=\"https://www.uptodate.com/contents/clinical-manifestations-and-diagnosis-of-pulmonary-sarcoidosis/abstract/79\" class=\"nounderline abstract_t\">Myers JL, Tazelaar HD. Challenges in pulmonary fibrosis: 6--Problematic granulomatous lung disease. Thorax 2008; 63:78.</a></li><li><a href=\"https://www.uptodate.com/contents/clinical-manifestations-and-diagnosis-of-pulmonary-sarcoidosis/abstract/80\" class=\"nounderline abstract_t\">Mukhopadhyay S, Wilcox BE, Myers JL, et al. Pulmonary necrotizing granulomas of unknown cause: clinical and pathologic analysis of 131 patients with completely resected nodules. Chest 2013; 144:813.</a></li><li><a href=\"https://www.uptodate.com/contents/clinical-manifestations-and-diagnosis-of-pulmonary-sarcoidosis/abstract/81\" class=\"nounderline abstract_t\">Aubry MC. Necrotizing granulomatous inflammation: what does it mean if your special stains are negative? Mod Pathol 2012; 25 Suppl 1:S31.</a></li><li><a href=\"https://www.uptodate.com/contents/clinical-manifestations-and-diagnosis-of-pulmonary-sarcoidosis/abstract/82\" class=\"nounderline abstract_t\">Brincker H. Coexistence of sarcoidosis and malignant disease: causality or coincidence? Sarcoidosis 1989; 6:31.</a></li><li><a href=\"https://www.uptodate.com/contents/clinical-manifestations-and-diagnosis-of-pulmonary-sarcoidosis/abstract/83\" class=\"nounderline abstract_t\">Ojeda H, Sardi A, Totoonchie A. Sarcoidosis of the breast: implications for the general surgeon. Am Surg 2000; 66:1144.</a></li><li><a href=\"https://www.uptodate.com/contents/clinical-manifestations-and-diagnosis-of-pulmonary-sarcoidosis/abstract/84\" class=\"nounderline abstract_t\">Toner GC, Bosl GJ. Sarcoidosis, &quot;Sarcoid-like lymphadenopathy,&quot; and testicular germ cell tumors. Am J Med 1990; 89:651.</a></li><li><a href=\"https://www.uptodate.com/contents/clinical-manifestations-and-diagnosis-of-pulmonary-sarcoidosis/abstract/85\" class=\"nounderline abstract_t\">Nakamura M, Iemura A, Kojiro M, et al. Leiomyosarcoma of the rectum with sarcoid-like reaction--a case report. Kurume Med J 1990; 37:171.</a></li><li><a href=\"https://www.uptodate.com/contents/clinical-manifestations-and-diagnosis-of-pulmonary-sarcoidosis/abstract/86\" class=\"nounderline abstract_t\">Campbell F, Douglas-Jones AG. Sarcoid-like granulomas in primary renal cell carcinoma. Sarcoidosis 1993; 10:128.</a></li><li><a href=\"https://www.uptodate.com/contents/clinical-manifestations-and-diagnosis-of-pulmonary-sarcoidosis/abstract/87\" class=\"nounderline abstract_t\">Newman TG, Minkowitz S, Hanna A, et al. Coexistent sarcoidosis and HIV infection. A comparison of bronchoalveolar and peripheral blood lymphocytes. Chest 1992; 102:1899.</a></li><li><a href=\"https://www.uptodate.com/contents/clinical-manifestations-and-diagnosis-of-pulmonary-sarcoidosis/abstract/88\" class=\"nounderline abstract_t\">Haramati LB, Lee G, Singh A, et al. Newly diagnosed pulmonary sarcoidosis in HIV-infected patients. Radiology 2001; 218:242.</a></li><li><a href=\"https://www.uptodate.com/contents/clinical-manifestations-and-diagnosis-of-pulmonary-sarcoidosis/abstract/89\" class=\"nounderline abstract_t\">Chalayer &Eacute;, Bachy E, Occelli P, et al. Sarcoidosis and lymphoma: a comparative study. QJM 2015; 108:871.</a></li><li><a href=\"https://www.uptodate.com/contents/clinical-manifestations-and-diagnosis-of-pulmonary-sarcoidosis/abstract/90\" class=\"nounderline abstract_t\">Chen J, Carter R 3rd, Maoz D, et al. Breast Cancer and Sarcoidosis: Case Series and Review of the Literature. Breast Care (Basel) 2015; 10:137.</a></li><li><a href=\"https://www.uptodate.com/contents/clinical-manifestations-and-diagnosis-of-pulmonary-sarcoidosis/abstract/91\" class=\"nounderline abstract_t\">Paparel P, Devonec M, Perrin P, et al. Association between sarcoidosis and testicular carcinoma: a diagnostic pitfall. Sarcoidosis Vasc Diffuse Lung Dis 2007; 24:95.</a></li><li><a href=\"https://www.uptodate.com/contents/clinical-manifestations-and-diagnosis-of-pulmonary-sarcoidosis/abstract/92\" class=\"nounderline abstract_t\">Wildner D, Boxberger F, Wein A, et al. Granulomatous lung disease requiring mechanical ventilation induced by a single application of oxaliplatin-based chemotherapy for colorectal cancer: a case report. Case Rep Oncol Med 2013; 2013:683948.</a></li><li><a href=\"https://www.uptodate.com/contents/clinical-manifestations-and-diagnosis-of-pulmonary-sarcoidosis/abstract/93\" class=\"nounderline abstract_t\">Sekhri A, Palaniswamy C, Kurmayagari K, et al. Interstitial lung disease associated with azacitidine use: a case report. Am J Ther 2012; 19:e98.</a></li><li><a href=\"https://www.uptodate.com/contents/clinical-manifestations-and-diagnosis-of-pulmonary-sarcoidosis/abstract/94\" class=\"nounderline abstract_t\">Vital Durand D, Durieu I, Rousset H. [Toxic or drug-induced granulomatous reactions]. Rev Med Interne 2008; 29:33.</a></li><li><a href=\"https://www.uptodate.com/contents/clinical-manifestations-and-diagnosis-of-pulmonary-sarcoidosis/abstract/95\" class=\"nounderline abstract_t\">Howard L, Gopalan D, Griffiths M, Mahadeva R. Sirolimus-induced pulmonary hypersensitivity associated with a CD4 T-cell infiltrate. Chest 2006; 129:1718.</a></li><li><a href=\"https://www.uptodate.com/contents/clinical-manifestations-and-diagnosis-of-pulmonary-sarcoidosis/abstract/96\" class=\"nounderline abstract_t\">de Kerviler E, Tr&eacute;daniel J, Revlon G, et al. Fluoxetin-induced pulmonary granulomatosis. Eur Respir J 1996; 9:615.</a></li><li><a href=\"https://www.uptodate.com/contents/clinical-manifestations-and-diagnosis-of-pulmonary-sarcoidosis/abstract/97\" class=\"nounderline abstract_t\">Chang H, Klein JS, Norotsky M, Cooper K. Granulomatous chest disease following intravesical bacillus Calmette-Guerin immunotherapy. J Thorac Imaging 2004; 19:60.</a></li><li><a href=\"https://www.uptodate.com/contents/clinical-manifestations-and-diagnosis-of-pulmonary-sarcoidosis/abstract/98\" class=\"nounderline abstract_t\">Judson MA, Baughman RP, Teirstein AS, et al. Defining organ involvement in sarcoidosis: the ACCESS proposed instrument. ACCESS Research Group. A Case Control Etiologic Study of Sarcoidosis. Sarcoidosis Vasc Diffuse Lung Dis 1999; 16:75.</a></li><li><a href=\"https://www.uptodate.com/contents/clinical-manifestations-and-diagnosis-of-pulmonary-sarcoidosis/abstract/99\" class=\"nounderline abstract_t\">Burke RR, Rybicki BA, Rao DS. Calcium and vitamin D in sarcoidosis: how to assess and manage. Semin Respir Crit Care Med 2010; 31:474.</a></li><li><a href=\"https://www.uptodate.com/contents/clinical-manifestations-and-diagnosis-of-pulmonary-sarcoidosis/abstract/100\" class=\"nounderline abstract_t\">Iannuzzi MC, Rybicki BA, Teirstein AS. Sarcoidosis. N Engl J Med 2007; 357:2153.</a></li><li><a href=\"https://www.uptodate.com/contents/clinical-manifestations-and-diagnosis-of-pulmonary-sarcoidosis/abstract/101\" class=\"nounderline abstract_t\">Ungprasert P, Crowson CS, Matteson EL. Association of Sarcoidosis With Increased Risk of VTE: A Population-Based Study, 1976 to 2013. Chest 2017; 151:425.</a></li><li><a href=\"https://www.uptodate.com/contents/clinical-manifestations-and-diagnosis-of-pulmonary-sarcoidosis/abstract/102\" class=\"nounderline abstract_t\">Yaqoob ZJ, Al-Kindi SG, Zein JG. Sarcoidosis and Risk of VTE: Validation With Big Data. Chest 2017; 151:1398.</a></li><li><a href=\"https://www.uptodate.com/contents/clinical-manifestations-and-diagnosis-of-pulmonary-sarcoidosis/abstract/103\" class=\"nounderline abstract_t\">Lachkar S, Dominique S, Thiberville L, et al. [Aspergillosis and sarcoidosis]. Rev Mal Respir 2007; 24:943.</a></li><li><a href=\"https://www.uptodate.com/contents/clinical-manifestations-and-diagnosis-of-pulmonary-sarcoidosis/abstract/104\" class=\"nounderline abstract_t\">Jamilloux Y, Valeyre D, Lortholary O, et al. The spectrum of opportunistic diseases complicating sarcoidosis. Autoimmun Rev 2015; 14:64.</a></li><li><a href=\"https://www.uptodate.com/contents/clinical-manifestations-and-diagnosis-of-pulmonary-sarcoidosis/abstract/105\" class=\"nounderline abstract_t\">Dannaoui E, Garcia-Hermoso D, Naccache JM, et al. Use of voriconazole in a patient with aspergilloma caused by an itraconazole-resistant strain of Aspergillus fumigatus. J Med Microbiol 2006; 55:1457.</a></li></ol></div><div id=\"topicVersionRevision\">Topic 4353 Version 26.0</div></div>","outline":"<div id=\"outlineSections\"><h2>Topic Outline</h2><ul id=\"innerOutline\"><li class=\"sr-button\"><a href=\"#H43\"><span>SUMMARY &amp; RECOMMENDATIONS</span></a></li><li><a href=\"#H1\" id=\"outline-link-H1\">INTRODUCTION</a></li><li><a href=\"#H2\" id=\"outline-link-H2\">EPIDEMIOLOGY</a></li><li><a href=\"#H3\" id=\"outline-link-H3\">ETIOLOGY</a></li><li><a href=\"#H4\" id=\"outline-link-H4\">CLINICAL MANIFESTATIONS</a><ul><li><a href=\"#H5\" id=\"outline-link-H5\">Adolescents and adults</a></li><li><a href=\"#H6\" id=\"outline-link-H6\">Children</a></li></ul></li><li><a href=\"#H3513219\" id=\"outline-link-H3513219\">EVALUATION</a><ul><li><a href=\"#H3513505\" id=\"outline-link-H3513505\">Laboratory testing</a><ul><li><a href=\"#H3513606\" id=\"outline-link-H3513606\">- Serum markers</a></li><li><a href=\"#H520193235\" id=\"outline-link-H520193235\">- Kveim test</a></li></ul></li><li><a href=\"#H520193263\" id=\"outline-link-H520193263\">Testing for tuberculosis</a></li><li><a href=\"#H7\" id=\"outline-link-H7\">Pulmonary imaging</a><ul><li><a href=\"#H8\" id=\"outline-link-H8\">- Chest radiograph</a></li><li><a href=\"#H14\" id=\"outline-link-H14\">- HRCT scan</a></li><li><a href=\"#H15\" id=\"outline-link-H15\">- FDG-PET scan</a></li><li><a href=\"#H16\" id=\"outline-link-H16\">- Other radiotracer scanning</a></li></ul></li><li><a href=\"#H34\" id=\"outline-link-H34\">Pulmonary function testing</a></li></ul></li><li><a href=\"#H272446561\" id=\"outline-link-H272446561\">DIAGNOSIS</a><ul><li><a href=\"#H37\" id=\"outline-link-H37\">Diagnostic approach</a></li><li><a href=\"#H272446495\" id=\"outline-link-H272446495\">Choice of biopsy site</a></li><li><a href=\"#H272445606\" id=\"outline-link-H272445606\">Bronchoscopy</a></li><li><a href=\"#H272446331\" id=\"outline-link-H272446331\">Endoscopic ultrasound guided needle aspiration</a></li><li><a href=\"#H272446222\" id=\"outline-link-H272446222\">Surgical biopsy of mediastinum and lung</a></li><li><a href=\"#H272446686\" id=\"outline-link-H272446686\">Histopathology</a></li></ul></li><li><a href=\"#H3513152\" id=\"outline-link-H3513152\">DIFFERENTIAL DIAGNOSIS</a></li><li><a href=\"#H272445441\" id=\"outline-link-H272445441\">INITIAL ASSESSMENT OF DISEASE EXTENT</a></li><li><a href=\"#H41\" id=\"outline-link-H41\">MONITORING</a></li><li><a href=\"#H3170426885\" id=\"outline-link-H3170426885\">COMPLICATIONS</a></li><li><a href=\"#H1163815402\" id=\"outline-link-H1163815402\">SOCIETY GUIDELINE LINKS</a></li><li><a href=\"#PATIENT_INFORMATION\" id=\"outline-link-H42\">INFORMATION FOR PATIENTS</a></li><li><a href=\"#H43\" id=\"outline-link-H43\">SUMMARY AND RECOMMENDATIONS</a></li><li><a href=\"#references\">REFERENCES</a></li></ul></div><div><h2>GRAPHICS <a href=\"#\" id=\"viewAllGraphicsLink\">View All</a></h2><div id=\"outlineGraphics\"><ul><li><div id=\"PULM/4353|DiagnosticImage\" class=\"openRelatedGraphics\"><a href=\"#\" title=\"DIAGNOSTIC IMAGES\">DIAGNOSTIC IMAGES</a></div><ul><li><a href=\"image.htm?imageKey=PULM/58018\" class=\"graphic graphic_diagnosticimage\">- Hilar adenopathy PA</a></li><li><a href=\"image.htm?imageKey=PULM/78632\" class=\"graphic graphic_diagnosticimage\">- Sarcoidosis stage II PA</a></li><li><a href=\"image.htm?imageKey=PULM/51488\" class=\"graphic graphic_diagnosticimage\">- Interstitial sarcoidosis CT</a></li><li><a href=\"image.htm?imageKey=PULM/68742\" class=\"graphic graphic_diagnosticimage\">- Advanced sarcoidosis PA</a></li><li><a href=\"image.htm?imageKey=PULM/69424\" class=\"graphic graphic_diagnosticimage\">- Stage II sarcoidosis CT</a></li><li><a href=\"image.htm?imageKey=PULM/56447\" class=\"graphic graphic_diagnosticimage\">- Pseudoalveolar sarcoidosis CT</a></li><li><a href=\"image.htm?imageKey=PULM/79110\" class=\"graphic graphic_diagnosticimage\">- Scarring in sarcoidosis CT</a></li><li><a href=\"image.htm?imageKey=PULM/80035\" class=\"graphic graphic_diagnosticimage\">- Miliary sarcoidosis CT</a></li></ul></li><li><div id=\"PULM/4353|FIG\" class=\"openRelatedGraphics\"><a href=\"#\" title=\"FIGURES\">FIGURES</a></div><ul><li><a href=\"image.htm?imageKey=ENDO/65360\" class=\"graphic graphic_figure\">- Vit D metabolism</a></li></ul></li><li><div id=\"PULM/4353|PIC\" class=\"openRelatedGraphics\"><a href=\"#\" title=\"PICTURES\">PICTURES</a></div><ul><li><a href=\"image.htm?imageKey=PULM/67837\" class=\"graphic graphic_picture\">- Transbronchial biopsy sarcoid</a></li><li><a href=\"image.htm?imageKey=PULM/67903\" class=\"graphic graphic_picture\">- Nodular sarcoidosis</a></li><li><a href=\"image.htm?imageKey=PULM/111424\" class=\"graphic graphic_picture\">- Endobronchial sarcoidosis</a></li><li><a href=\"image.htm?imageKey=PULM/83308\" class=\"graphic graphic_picture\">- Sarcoid granuloma with an asteroid body</a></li><li><a href=\"image.htm?imageKey=PULM/83306\" class=\"graphic graphic_picture\">- Sarcoid granuloma with Schaumann body</a></li><li><a href=\"image.htm?imageKey=PULM/83307\" class=\"graphic graphic_picture\">- Sarcoid granuloma with calcium oxalate crystal</a></li></ul></li><li><div id=\"PULM/4353|TAB\" class=\"openRelatedGraphics\"><a href=\"#\" title=\"TABLES\">TABLES</a></div><ul><li><a href=\"image.htm?imageKey=PULM/76046\" class=\"graphic graphic_table\">- Sarcoid organ involvement</a></li><li><a href=\"image.htm?imageKey=PULM/93244\" class=\"graphic graphic_table\">- Causes of an elevated serum ACE level</a></li><li><a href=\"image.htm?imageKey=PULM/65081\" class=\"graphic graphic_table\">- ACCESS criteria sarcoid A</a></li><li><a href=\"image.htm?imageKey=PULM/72769\" class=\"graphic graphic_table\">- ACCESS criteria sarcoid B</a></li><li><a href=\"image.htm?imageKey=PULM/67386\" class=\"graphic graphic_table\">- Sarcoid monitoring</a></li></ul></li></ul></div></div><div><h2>RELATED TOPICS</h2><div id=\"outlineTopics\"><ul><li class=\"plainItem\"><a href=\"topic.htm?path=approach-to-diagnosis-of-latent-tuberculosis-infection-tuberculosis-screening-in-adults\" class=\"medical medical_review\">Approach to diagnosis of latent tuberculosis infection (tuberculosis screening) in adults</a></li><li class=\"plainItem\"><a href=\"topic.htm?path=basic-principles-and-technique-of-bronchoalveolar-lavage\" class=\"medical medical_review\">Basic principles and technique of bronchoalveolar lavage</a></li><li class=\"plainItem\"><a href=\"topic.htm?path=bronchocentric-granulomatosis\" class=\"medical medical_review\">Bronchocentric granulomatosis</a></li><li class=\"plainItem\"><a href=\"topic.htm?path=chronic-beryllium-disease-berylliosis\" class=\"medical medical_review\">Chronic beryllium disease (berylliosis)</a></li><li class=\"plainItem\"><a href=\"topic.htm?path=clinical-features-and-diagnosis-of-eosinophilic-granulomatosis-with-polyangiitis-churg-strauss\" class=\"medical medical_review\">Clinical features and diagnosis of eosinophilic granulomatosis with polyangiitis (Churg-Strauss)</a></li><li class=\"plainItem\"><a href=\"topic.htm?path=clinical-manifestations-and-complications-of-pulmonary-tuberculosis\" class=\"medical medical_review\">Clinical manifestations and complications of pulmonary tuberculosis</a></li><li class=\"plainItem\"><a href=\"topic.htm?path=clinical-manifestations-and-diagnosis-of-blastomycosis\" class=\"medical medical_review\">Clinical manifestations and diagnosis of blastomycosis</a></li><li class=\"plainItem\"><a href=\"topic.htm?path=clinical-manifestations-and-diagnosis-of-cardiac-sarcoidosis\" class=\"medical medical_review\">Clinical manifestations and diagnosis of cardiac sarcoidosis</a></li><li class=\"plainItem\"><a href=\"topic.htm?path=clinical-manifestations-and-diagnosis-of-chronic-pulmonary-aspergillosis\" class=\"medical medical_review\">Clinical manifestations and diagnosis of chronic pulmonary aspergillosis</a></li><li class=\"plainItem\"><a href=\"topic.htm?path=clinical-presentation-and-diagnosis-of-pneumocystis-pulmonary-infection-in-hiv-infected-patients\" class=\"medical medical_review\">Clinical presentation and diagnosis of Pneumocystis pulmonary infection in HIV-infected patients</a></li><li class=\"plainItem\"><a href=\"topic.htm?path=computed-tomographic-and-positron-emission-tomographic-scanning-of-pulmonary-nodules\" class=\"medical medical_review\">Computed tomographic and positron emission tomographic scanning of pulmonary nodules</a></li><li class=\"plainItem\"><a href=\"topic.htm?path=cutaneous-manifestations-of-sarcoidosis\" class=\"medical medical_review\">Cutaneous manifestations of sarcoidosis</a></li><li class=\"plainItem\"><a href=\"topic.htm?path=diagnosis-and-treatment-of-pulmonary-histoplasmosis\" class=\"medical medical_review\">Diagnosis and treatment of pulmonary histoplasmosis</a></li><li class=\"plainItem\"><a href=\"topic.htm?path=diagnosis-of-hypersensitivity-pneumonitis-extrinsic-allergic-alveolitis\" class=\"medical medical_review\">Diagnosis of hypersensitivity pneumonitis (extrinsic allergic alveolitis)</a></li><li class=\"plainItem\"><a href=\"topic.htm?path=diagnostic-evaluation-of-a-pleural-effusion-in-adults-initial-testing\" class=\"medical medical_review\">Diagnostic evaluation of a pleural effusion in adults: Initial testing</a></li><li class=\"plainItem\"><a href=\"topic.htm?path=endobronchial-ultrasound-indications-contraindications-and-complications\" class=\"medical medical_review\">Endobronchial ultrasound: Indications, contraindications, and complications</a></li><li class=\"plainItem\"><a href=\"topic.htm?path=endobronchial-ultrasound-technical-aspects\" class=\"medical medical_review\">Endobronchial ultrasound: Technical aspects</a></li><li class=\"plainItem\"><a href=\"topic.htm?path=endoscopic-ultrasound-guided-sampling-of-the-mediastinum-technique-indications-contraindications-and-complications\" class=\"medical medical_review\">Endoscopic ultrasound-guided sampling of the mediastinum: Technique, indications, contraindications, and complications</a></li><li class=\"plainItem\"><a href=\"topic.htm?path=erdheim-chester-disease\" class=\"medical medical_review\">Erdheim-Chester disease</a></li><li class=\"plainItem\"><a href=\"topic.htm?path=extrapulmonary-manifestations-of-sarcoidosis\" class=\"medical medical_review\">Extrapulmonary manifestations of sarcoidosis</a></li><li class=\"plainItem\"><a href=\"topic.htm?path=foreign-body-granulomatosis\" class=\"medical medical_review\">Foreign body granulomatosis</a></li><li class=\"plainItem\"><a href=\"topic.htm?path=gastrointestinal-and-hepatic-sarcoidosis\" class=\"medical medical_review\">Gastrointestinal and hepatic sarcoidosis</a></li><li class=\"plainItem\"><a href=\"topic.htm?path=high-resolution-computed-tomography-of-the-lungs\" class=\"medical medical_review\">High resolution computed tomography of the lungs</a></li><li class=\"plainItem\"><a href=\"topic.htm?path=immune-reconstitution-inflammatory-syndrome\" class=\"medical medical_review\">Immune reconstitution inflammatory syndrome</a></li><li class=\"plainItem\"><a href=\"topic.htm?path=interpretation-of-lung-biopsy-results-in-interstitial-lung-disease\" class=\"medical medical_review\">Interpretation of lung biopsy results in interstitial lung disease</a></li><li class=\"plainItem\"><a href=\"topic.htm?path=neurologic-sarcoidosis\" class=\"medical medical_review\">Neurologic sarcoidosis</a></li><li class=\"plainItem\"><a href=\"topic.htm?path=overview-of-minimally-invasive-thoracic-surgery\" class=\"medical medical_review\">Overview of minimally invasive thoracic surgery</a></li><li class=\"plainItem\"><a href=\"topic.htm?path=overview-of-nontuberculous-mycobacterial-infections-in-hiv-negative-patients\" class=\"medical medical_review\">Overview of nontuberculous mycobacterial infections in HIV-negative patients</a></li><li class=\"plainItem\"><a href=\"topic.htm?path=overview-of-pulmonary-function-testing-in-adults\" class=\"medical medical_review\">Overview of pulmonary function testing in adults</a></li><li class=\"plainItem\"><a href=\"topic.htm?path=overview-of-vitamin-d\" class=\"medical medical_review\">Overview of vitamin D</a></li><li class=\"plainItem\"><a href=\"topic.htm?path=pathology-and-pathogenesis-of-sarcoidosis\" class=\"medical medical_review\">Pathology and pathogenesis of sarcoidosis</a></li><li class=\"plainItem\"><a href=\"topic.htm?path=sarcoidosis-beyond-the-basics\" class=\"medical medical_patient\">Patient education: Sarcoidosis (Beyond the Basics)</a></li><li class=\"plainItem\"><a href=\"topic.htm?path=sarcoidosis-the-basics\" class=\"medical medical_basics\">Patient education: Sarcoidosis (The Basics)</a></li><li class=\"plainItem\"><a href=\"topic.htm?path=pulmonary-langerhans-cell-histiocytosis\" class=\"medical medical_review\">Pulmonary Langerhans cell histiocytosis</a></li><li class=\"plainItem\"><a href=\"topic.htm?path=pulmonary-complications-of-primary-immunodeficiencies\" class=\"medical medical_review\">Pulmonary complications of primary immunodeficiencies</a></li><li class=\"plainItem\"><a href=\"topic.htm?path=pulmonary-hypertension-due-to-lung-disease-and-or-hypoxemia-group-3-pulmonary-hypertension-epidemiology-pathogenesis-and-diagnostic-evaluation-in-adults\" class=\"medical medical_review\">Pulmonary hypertension due to lung disease and/or hypoxemia (group 3 pulmonary hypertension): Epidemiology, pathogenesis, and diagnostic evaluation in adults</a></li><li class=\"plainItem\"><a href=\"topic.htm?path=pulmonary-hypertension-due-to-lung-disease-and-or-hypoxemia-group-3-pulmonary-hypertension-treatment-and-prognosis\" class=\"medical medical_review\">Pulmonary hypertension due to lung disease and/or hypoxemia (group 3 pulmonary hypertension): Treatment and prognosis</a></li><li class=\"plainItem\"><a href=\"topic.htm?path=pulmonary-lymphomatoid-granulomatosis\" class=\"medical medical_review\">Pulmonary lymphomatoid granulomatosis</a></li><li class=\"plainItem\"><a href=\"topic.htm?path=renal-disease-in-sarcoidosis\" class=\"medical medical_review\">Renal disease in sarcoidosis</a></li><li class=\"plainItem\"><a href=\"topic.htm?path=respiratory-tract-involvement-in-granulomatosis-with-polyangiitis-and-microscopic-polyangiitis\" class=\"medical medical_review\">Respiratory tract involvement in granulomatosis with polyangiitis and microscopic polyangiitis</a></li><li class=\"plainItem\"><a href=\"topic.htm?path=role-of-bronchoalveolar-lavage-in-diagnosis-of-interstitial-lung-disease\" class=\"medical medical_review\">Role of bronchoalveolar lavage in diagnosis of interstitial lung disease</a></li><li class=\"plainItem\"><a href=\"topic.htm?path=role-of-lung-biopsy-in-the-diagnosis-of-interstitial-lung-disease\" class=\"medical medical_review\">Role of lung biopsy in the diagnosis of interstitial lung disease</a></li><li class=\"plainItem\"><a href=\"topic.htm?path=sarcoid-arthropathy\" class=\"medical medical_review\">Sarcoid arthropathy</a></li><li class=\"plainItem\"><a href=\"topic.htm?path=society-guideline-links-sarcoidosis\" class=\"medical medical_society_guidelines\">Society guideline links: Sarcoidosis</a></li><li class=\"plainItem\"><a href=\"topic.htm?path=surgical-evaluation-of-mediastinal-lymphadenopathy\" class=\"medical medical_review\">Surgical evaluation of mediastinal lymphadenopathy</a></li><li class=\"plainItem\"><a href=\"topic.htm?path=transbronchial-needle-aspiration\" class=\"medical medical_review\">Transbronchial needle aspiration</a></li><li class=\"plainItem\"><a href=\"topic.htm?path=treatment-of-chronic-pulmonary-aspergillosis\" class=\"medical medical_review\">Treatment of chronic pulmonary aspergillosis</a></li><li class=\"plainItem\"><a href=\"topic.htm?path=treatment-of-pulmonary-sarcoidosis-disease-refractory-to-glucocorticoid-therapy\" class=\"medical medical_review\">Treatment of pulmonary sarcoidosis: Disease refractory to glucocorticoid therapy</a></li><li class=\"plainItem\"><a href=\"topic.htm?path=treatment-of-pulmonary-sarcoidosis-initial-therapy-with-glucocorticoids\" class=\"medical medical_review\">Treatment of pulmonary sarcoidosis: Initial therapy with glucocorticoids</a></li><li class=\"plainItem\"><a href=\"topic.htm?path=use-of-interferon-gamma-release-assays-for-diagnosis-of-latent-tuberculosis-infection-tuberculosis-screening-in-adults\" class=\"medical medical_review\">Use of interferon-gamma release assays for diagnosis of latent tuberculosis infection (tuberculosis screening) in adults</a></li></ul></div></div>","javascript":null}